PP Singh

CURRICULUM VITAE
PROF. PRATI PAL SINGH Ph. D., F. N. A. Sc., F. I. A. M. Sc.

House No. Type VI/3
National Institute of Pharmaceutical
Education and Research Campus
Sector-67, Phase-X
S. A. S. Nagar–160 062, Punjab, INDIA
Phone: +91-(0)-0172 –2 214682-87 (O); +91-(0)-0172-2214698 (R)
Fax: +91-(0)-0172–2214692 (O) ; Mobile: 09417196015, 08847422653
E-mail: drppsingh2016@gmail.com drppsingh2005@gmail.com
PRESENT PAY Basic pay: Rs. 77, 500/- (Pay band 4; Band pay: Rs. 67, 000;
Academic Grade pay: Rs. 10, 500)
EDUCATION*
1976-1980 Ph. D.; Title: “Experimental Studies on Some Chemotherapeutic and
Immunological Aspects of Primate Malaria (Plasmodium knowlesi
infection)”; work done at Central Drug Research Institute, Lucknow; degree
awarded by Chhatrapati Shahu Ji Maharaj University (formerly Kanpur
University), Kanpur, U. P.
1975-1976 Proficiency in French; University of Lucknow, Lucknow.
1973-1975 M. Sc.; Zoology (Physiology/Entomology); University of Lucknow. (I

division and II position in order of merit in the university).
1971-1973 B. Sc.; Chemistry, Botany, Zoology and Gen. English; University of

Lucknow, Lucknow.
1988 Indo-US Workshop on Cell Mediated Immunity in Relation to Tropical

Diseases, Lucknow.
Dr. Prati Pal Singh

2
1989 IUIS -WHO-AIIMS Advanced Immunology Course, New Delhi.
1991 Indo-US Workshop on Current Approaches for Receptor Studies in

Neurobiology, Lucknow.
1992 Course on Management of Research Programmes, Council of Scientific and

Industrial Research, New Delhi.
2003 Induction Training Programme for Faculty of NIPER by Education and

Educational Management Department, National Institute of Technical
Teacher’s Education and Research, Chandigarh.
* Process for the submission of D. Sc. degree thesis titled “Studies on some Parasitic
Protozoans of National Health and Pharmaceutical Importance” to C. S. J. M.
University, Kanpur has been started. Thesis synopsis submitted on Jan. 06, 2006.
Total pages 43
PROFESSIONAL POSITIONS (in reverse chronological order)*
2004–present Professor, Pharmacology and Toxicology, and In-charge, Centre for

Infectious Diseases, National Institute of Pharmaceutical Education and
Research, S.A.S. Nagar. Ex. Associate Dean (academic affairs). Ex.
Senator.
1997–2004 Associate Professor, National Institute of Pharmaceutical Education and
Research, S.A.S. Nagar.
1991–1996 Scientist-C (Group Leader), Division of Microbiology, Central Drug
Research Institute, Lucknow.
1988–1991 Scientist-B, Division of Microbiology, Central Drug Research Institute,
Lucknow.
1987–1988 Scientist (Pool Officer), Division of Microbiology, Central Drug Research
Institute, Lucknow.
1986 Research Associate, Department of FCPM, Stanford University Medical
Center, Stanford, CA, USA.
1984–1985 Research Associate, Department of Microbiology, The Ohio State
University, Columbus, OH, USA.
1983–1984 Scientist-in-charge, Department of Protozoology, Hindustan Ciba-Giegy
Research Centre, Mumbai.
1979–1982 Senior Scientific Asstt., Research Centre, Indian Drugs and
Pharmaceuticals Ltd., Hyderabad.
1976–1979 Junior Research Fellow, Division of Microbiology, Central Drug Research
Institute, Lucknow.
*I was invited to join on deputation as Professor in the Department of Pharmaceutical Sciences, Guru
Jambheshwar University of Science and Technology, Hisar, vide their letter No. F-III/06/1061 dated April
22, 2006.
PERSONAL DETAILS
Dr. Prati Pal Singh

3
Date of birth, July 05, 1954; Age, 64 years; height, 5 feet 5 ½ inches; weight, 65 kg; health,
excellent; married; one daughter 31 years; religion, Hindu; hobby–intelligent discussions,
long morning walks, chess, photography, music.
MEMBERSHIPS OF PROFESSIONAL SOCIETIES/ORGANIZATIONS
1. Member, The Neuro Network, USA.

2. Member, International Society for Infectious Diseases, USA.
3. Ex. Councilor-at-large (non-US), Society on NeuroImmune Pharmacology,
USA.
4. Life Member, The National Academy of Sciences, India, Allahabad.
5. Life Member, Inflammation Research Association, U.S.A.
6. Member, International Brain Research Organization, France.
7. Life Member, Indian Immunology Society.
8. Life Member, Indian Academy of Neurosciences.
9. Life Member, Indian Science Congress Association.
10. Life Member, Indian Society for Parasitology.
11. Life Member, U. P. Association for the Advancement of Science.
12. Life Member, Association of Microbiologists of India.
13. Life Member, Indian Pharmacology Society.
14. Founder Member, Molecular Immunology Forum.
15. Ex. Vice-President, Indian Society of Chemists and Biologists.
AWARDS/HONOURS
 Member, Senate, National Institute of Pharmaceutical Education and Research, S.

A. S. Nagar.
 Peer, Perception Component, National Institutional Ranking Framework (NIRF),
India Rankings-2018.
 Expert Reviewer, research grant proposals, Kerala State Council for Science,
Technology and Environment, Thiruvananthapuram, Kerala (2018).
 Evaluator, Dr. S. Vasudev Award, Kerala State Council for Science, Technology
and Environment, Thiruvananthapuram, Kerala (2017).
 Member, Senate, National Institute of Pharmaceutical Education and Research, S.
A. S. Nagar.
 Ex. Associate Dean (Academic Affairs), National Institute of Pharmaceutical
Education and Research, S. A. S. Nagar.
 Winner, 2018 Albert Nelson Marquis Lifetime Achievement Award.
 Editor, Pharmaceutical Drug Regulatory Affairs Journal.
 Member, Editorial Board, Journal of Infectious Diseases and Epidemiology,
USA.
 Member, Editorial Board, Source Journal of Pharmaceutical Sciences, USA.
 Member, Editorial Board, Journal of Pharmaceutical Microbiology, USA.
 Member, Editorial Board, Mathews Journal of Immunology & Allergy, USA
 Member, Editorial Board, Journal of Analytical and Pharmaceutical Research,
USA.
Dr. Prati Pal Singh

4
 Member, Editorial Board, Toxicology and Forensic Medicine-Open Journal,

USA.
 Member, IBCs Leading Health Professional of the World – 2015.
 Member, Advisory Committee, CSIR Young Scientist Award 2014 (Biological
Sciences).
 Member, Scientific Board, Research Institute for Pharmacy and Biochemistry,
Brno, Czech Republic, 2012.
 Executive Editor, Journal of Current Pharma Research
 Member, Editorial Board, International Bulletin of Pharmaceutical Sciences.
 Member, Editorial Board, Pharmaceutical Design and Current Perspective.
 Reviewer, Immunology and Infectious Diseases.
 Elected, At-Large Councilor (non-US) 2010, Society on Neuroimmune
Pharmacology, USA.
 Awarded financial support to participate in the 15th Society on Neuroimmune
Pharmacology conference, April 21-24, 2009, Wuhan, China.
 Elected, Fellow of the Indian Academy of Microbiological Sciences (2008).
 The Bill and Melinda Gates Foundation Global Health Travel Award 2008 to
attend the Keystone Symposia E3 Malaria: Immunology, Pathogenesis and Vaccine
Perspectives, Alpbach Congress Centrum, Alpbach, Austria, Austria, June 08-13,
2008.
 Selected as IBCs Leading Scientist of World 2008.
 Bioorganic & Medicinal Chemistry Most Cited Paper 2003–2006 Award.
Bioorganic and Med. Chem. 2004 12: 2501-2508.
 Member, Editorial Board, Journal of Neuroimmune Pharmacology, USA.
 Editor/Reviewer, Science Alert.
 National Institute on Drug Abuse, USA, Travel Grant Awardee (2006) for
participation in 12th Society on NeuroImmune Pharmacology Conference, Santa Fe,
New Mexico, USA.
 Editor-in-Chief, Journal of Parasitic Diseases (2006-2008).
 Member, Executive Committee, Indian Society for Parasitology.
 Member, Editorial Advisory Board, “Recent Patent Reviews on Anti-Infective
Drug Discovery”, Bentham Science, USA.
 Elected, Fellow of The National Academy of Sciences of India, Allahabad
(2004) for his contribution in the field of biotechnology, parasitology and
neuroimmunomodulation.
 Awarded, Indian Science Congress Association best presentation award in
Section: New Biology (including biochemistry, biophysics and molecular biology
& biotechnology), 2003.
 Selected for biographical inclusion in the Ninth Edition of International Directory
of Distinguished Leadership, 2000.
 Awarded, prestigious Tulsabai Somani Educational Trust 1992 award of the
Indian Academy of Neurosciences.
RECOGNITIONS
Dr. Prati Pal Singh

5
 Judge, Poster Session, First Annual Research Day Celebrations, Government

Medical College & Hospital, Chandigarh (October 15, 2018).
 Member, Site Visit Panel, Contract Research and Services Scheme (CRS),
Biotechnology Industry Research Assistance Council (BIRAC), Department of
Biotechnology for National Institute of Oceanography, Goa, (October 12, 2018).
 Invited Speaker, Dept. of Biotechnology, Mata Gujri College, Fatehgarh Sahib,
Punjab (September 07, 2018).
 Expert Evaluator, Kerala State Council for Science, Technology and Environment
research projects (2018)
 Resource Person and Invited Speaker, National Workshop on Computer Aided
Drug Design, Srinivasa Ramanujan Institute for Basic Sciences (Kerala State
Council for Science, Technology and Environment), Kottayam, Kerala (July 20-22,
2018).
 Expert Evaluator, Contract Research and Services Scheme (CRS),
Biotechnology Industry Research Assistance Council (BIRAC) (August 2018).
 Member, Site Visit Panel, Biotechnology Industry Research Assistance Council
(BIRAC), Department of Biotechnology for Integral Biosciences Private Limited,
NOIDA, UP (October 11, 2017).
 Expert Evaluator, Biotechnology Industry Partnership Programme (BIPP),
Biotechnology Industry Research Assistance Council (BIRAC), (April and August
2017). Small Business Innovation Research Initiative (SBIRI)
 Member, Expert Committee, Strategic Indo-Swedish Cooperative Innovation
Programme between DBT India-VINNOVA, Sweden. (Third Joint Call for
Proposals) April 11, 2017.
 Paper Coordinator, UGC approved e-pathshala (M. Sc. Biotechnology).
 Member, Site Visit Panel, Biotechnology Industry Research Assistance Council
(BIRAC), Department of Biotechnology for JNCASR and Anthem Biosciences
(June 22, 2015).
 Expert reviewer, Social Innovation Programme for Products Affordable &
Relevant to Societal Health (SPARSH), Biotechnology Industry Research
Assistance Council (BIRAC), (November 2016)
 Expert reviewer, Small Business Innovation Research Initiative (SBIRI),
Biotechnology Industry Research Assistance Council (BIRAC), (August 2016).
 Expert Evaluator, Contract Research and Services Scheme (CRS),
Biotechnology Industry Research Assistance Council (BIRAC) (October 2016).
 Member, State Level Co-ordination Committee, National Institute of
Pharmaceutical Education and Research, Rae Bareli, Ministry of Chemicals
and Fertilizers, Govt. of India.
 Nodal Officer, National Institute of Pharmaceutical Education and Research,
Rae Bareli, Ministry of Chemicals and Fertilizers, Govt. of India.
 Resource Person/Organizer, National Conference on Infectious Diseases:
Challenges and Opportunities in Research and Practice, Institute of Pharmacy,
Nirma University, Ahmedabad (Jan. 22-23, 2015).
 Member, Selection Committee, Faculty Positions, Institute of Pharmacy, Nirma
University, Ahmedabad (May 10, 2014).
 Member, Selection Committee, Faculty Positions in Biology, Indian Institute of
Technology, Rajasthan (IITJ), Jodhpur (Dec. 12, 2011).
 Nominated for Fellow, Indian National Science Academy (F.N.A.), New Delhi.
Dr. Prati Pal Singh
6
 Nominated for Fellow, Indian Science Academy (F. A. Sc.), Bangalore.

 Book Reviewer, “Conceptual Pharmacology” 2010 Edition, P. Jagadish Prasad,
University Press (India) Pvt. Ltd. (2013).
 Expert Evaluator, Kerala State Council for Science, Technology and Environment
research projects (2013-15).
 Expert Evaluator, Indo-Australia Biotechnology Fund (IABF) collaborative
projects (between DBT and DIISR), Dec. 2011.
 Chairman, Institutional Biosafety Committee, NIPER, S. A. S. Nagar.
 Ex-Chairman, Radiation Safety Committee, NIPER, S. A. S. Nagar.
 Member, Scientific Advisory Committee, ICMR Desert Medicine Research
Centre, Jodhpur (May 20-22, 2010).
 Chairman, Scientific Working Group on Nutrition, Biochemistry and NCDs (Feb.
18-19,2010)
 Member, Doctoral Committee, Ph. D. student, SRM University, Kattankulathur,
Tamil Nadu (2009).
 Expert, Research Grant Proposal Evaluation, Council of Scientific and Industrial
Research, New Delhi (2009).
 Member, Selection Committee, Pharmaceutical Sciences and Drug Research,
Punjabi University, Patiala (2008).
 Chairman, Selection Committee, Scientist B, National Institute of Occupational
Health (ICMR), Ahmedabad (2008).
 Organizing Secretary, “International Conference on Biotechnological
Approaches to Neuroimmunomodulation and Infectious Diseases”, Dec.11-13,
2008, NIPER, S. A. S. Nagar.
 Expert, Research Grant Proposal Evaluation, Department of Biotechnology, New
Delhi (2008).
 Invitee, The Third Open Forum on Key Issues in Tuberculosis Drug Development,
organized by TB Alliance, The Bill and Melinda Gates Foundation, The Stop TB
Partnership Working Group and Treatment Action Group, New Delhi (May 5-6,
2008).
 Member, Selection Committee, Scientist C, National Institute of Occupational
Health (ICMR), Ahmedabad (2008).
 Member, Scientific Advisory Committee, Desert Medicine Research Centre,
(ICMR), Jodhpur (2008).
 Member (Special Invitee), Scientific Advisory Committee, National Institute of
Occupational Health (ICMR), Ahmadabad (2008).
 Expert, Technology Information, Forecasting and Assessment Council (TIFAC),
New Delhi (2007).
 Evaluator, Research Grant Proposal, Department of Science and Technology, New
Delhi (2006).
 Expert Attendee, Expert Focus Group: MMV–Shin Poong Pyronaridine-
Artesunate Project Development Team, September 15, 2005, La Salle Notre Dame
de la Grande, Marseille, France.
 Evaluator, Research Grant Proposal, Council of Science and Technology, U.P.,
Lucknow (2005).
 Referee, Mini-Reviews in Medicinal Chemistry.
 Referee, Proc. of the Nat. Acad. of Sciences, India (Sec. B–Biol. Sciences)
Dr. Prati Pal Singh

7
 Referee, National Academy Science Letters.

 Chairman, Scientific Session: Toxicological Problems in Occupational Health,
International Conference on Health, Occupation and Environment, Nov. 1–3, 2004,
Industrial Toxicology Research Center, Lucknow.
 Senator, National Institute of Pharmaceutical Education and Research, S. A. S.
Nagar (2000–2004).
 Faculty member, Refresher Course in Zoology, Academic Staff College, Shimla
University, Shimla, 2004.
 Coordinator, NIPER Thrust Areas of Research: MALARIA and TUBERCULOSIS.
 Faculty member, Refresher Course in Zoology, Academic Staff College, Panjab
University, Chandigarh, 2000.
 Organizing Secretary, The Millennium Symposium Malaria 2000, NIPER, S. A.
S. Nagar, 2000.
 Organizing Secretary, Indo-US Symposium on Recombinant DNA Technology
and its Application in Drug Discovery, NIPER, S. A. S. Nagar, 1999.
 Joint-Organizing Secretary, National Conference on Chemistry and Biology of
Herbal Medicine, Lucknow, 1997.
 Treasurer, CSIR-SWA Silver Jubilee Symposium on Intellectual Property Rights
and Industrial Development in India–Health, Agriculture and Environment,
Lucknow, 1996.
 Member, Scientific and Publications Committee, First Annual Conference on
Chemistry, Biology and Health-Care, Lucknow, 1996.
 Faculty member, NAM and Third World Academy Workshop on Antimalarial
Evaluation and Biocide Assay for Control of Malaria, Lucknow, 1994.
 Faculty member, Refresher Course, Academic Staff College, University of
Lucknow, Lucknow, 1993.
 Faculty Member, UNESCO-CDRI Workshop on the Use of Pharmacological
Techniques for the Study of Natural Products, Lucknow, 1992.
 Member, R and D Highlights and Publications and, Finance Committees, CSIR
Golden Jubilee Symposium on Tropical Diseases: Molecular Biology and Control
Strategies, Lucknow, 1992.
 Member, Organizing Committee, CSIR Exposition on Medicinal Plants, CDRI,
Lucknow, 1989.
 Secretary, Scientific and Publications Committee, Symposium on Recent
Advances in Protozoan Diseases, November 28-29, Hind. Ciba-Geigy Ltd.,
Bombay, 1983.
 Referee, Indian Journal of Medical Research, 1983-84.
 Vice-President, Zoological Society, University of Lucknow, Lucknow, 1975.
BOOKS EDITED
 Prof. Prati Pal Singh and Prof. V. P. Sharma (Eds.). 2014. “Water and Health”
pp i-xxiii + 404, Springer India. ISBN: 978-81-322-1028-3 (Hardcover) 978-81-
322-2869-1 (Softcover) 978-81-322-1029-0 (e-Book); DOI 10.1007/978-81-322-
1029-0.
 Prof. Prati Pal Singh and Prof. V. P. Sharma (Eds.). 2009. Proceedings of the
National Academy of Sciences, India. Section B – Biological Sciences. Special
Dr. Prati Pal Singh

8
Issue titled “Human Parasitic Infections of Pharmaceutical and National Health

Importance”. pp 220, ISSN 0369-8211.
 Prof. Prati Pal Singh and Prof. R M Donahoe (Eds.). 2009. “Proceedings of
International Conference on Biotechnological Approaches to
Neuroimmunomodulation and Infectious Diseases”. pp i-xii + 508, ISBN 978-81-
8465-013-6.
VISITS ABROAD
 June 28, 2013: European Molecular Biology Laboratory, Hamburg, Germany.

(Invited Lecture)
 June 27, 2013: Institute of Medical Microbiology, Otto-van-Guericke University
Magdeburg, Germany. (Invited Lecture)
 June 22-26, 2013: Institute of Medical Microbiology, the Justus-Liebig University,
Giessen, Germany. (discussions for possible collaborative research projects funded
by some international funding agency)
 June 19-22, 2013: CNRS and University of Orleans, Orleans, France. (Invited
Lecture)
 October 25-30, 2010: Institute of Medical Microbiology, Justus Liebig University,
Giessen, Germany. (Invited Lecture)
 October 17-19, 2010: Annual General Assembly Meeting of the Indo-EU project
(FP7) titled “New Approaches to Target Tuberculosis”, London, UK.
 September 30, 2009: TSE System GmbH, Siemensstr., Bad Homburg, Germany.
(Invited Lecture)
 September 29, 2009: Klinik für Anaesthesiologie und operative Intensivmedizin,
Freie Universitüt Berlin, Charité-Campus Benjamin Franklin, 12200 Berlin,
Germany. (Invited Lecture)
 September 27-29, 2009: Annual General Assembly meeting of the Indo-EU project
(FP7) titled “New Approaches to Target Tuberculosis”, Berlin, Germany.
 September 25-27, 2009: Institute of Medical Microbiology, the Justus-Liebig
University, Giessen, Germany. (Invited Lecture and discussions for initiating
collaborative research projects funded by some international funding agency)
 April 21-25, 2009: 15th Annual Conference of Society on Neuroimmune
Pharmacology, Wuhan, China. (Invited Lecture)
 November 14-15, 2008: Institute of Medical Microbiology, Otto-van-Guericke
University Magdeburg, Germany. (Invited Lecture)
 November 10-13, 2008: Start-up meeting of the recently funded FP7 Indo-EU
project titled ““New Approaches to Target Tuberculosis””, Leuven, Belgium.
 June 15-17, 2008: Institute of Medical Microbiology, Otto-van-Guericke
University Magdeburg, Germany. (Invited Lecture)
 June 12-15, 2008: Department of Public Health-Microbiology-Virology,
University of Milan, Italy. (Invited Seminar)
 June 07-12, 2008: Keystone Symposia Conference, E3 “Malaria: Immunology,
Pathogenesis and Vaccine Perspectives”, Alpabach Congress Centrum, Alpabach,
Austria, Austria. (Bill and Melinda Gates Foundation Awardee)
 April 04-10, 2006: 12th Society on NeuroImmune Pharmacology Conference, Santa
Fe, New Mexico, USA. (Delegate)
Dr. Prati Pal Singh

9
 Sept. 16, 2005: Departement de Medecine Moleculaire, Institut Pasteur, Paris,

France. (Invited Lecture)
 Sept. 15, 2005: Genetique Experimentale et Moleculaire Institut de Transgenose,
Orleans, France. (Invited Lecture)
 Sept. 11-14, 2005: World Congress on “Medicine and Health in the Tropics”,
Marseille, France. (Delegate)
 Sept. 29-Oct. 02, 1999: The 4th International Congress of the International Society
for Neuroimmunomodulation, Lugano, Switzerland. (Delegate)
 Jan.–Aug. 1986: FCPM department, Stanford University Medical Center, Stanford,
CA, USA. (Research Associate)
 May, 1985: Division of Clinical Immunology and Allergy, Montreal General
Hospital, Montreal, Canada. (Visiting Fellow)
 Jul. 1984–Dec. 1985: Microbiology Department, The Ohio State University,
Columbus, OH, USA. (Post-Doctoral Research Associate)
RESEARCH EXPERIENCE (Forty two years)
Broad area of specialization: Life Sciences Education and Research

Specific areas of specialization: Parasitic and microbial infections (mainly malaria,
leishmaniasis, amoebiasis, trichmoniasis and tuberculosis): new drug discovery,
biotechnology, pharmaceutical sciences, bioimmunotherapy, vaccination and
pathogenesis; neuroimmunomodulation, inflammation, drug- and immune-toxicology, and
science administration and communication/editing.
Brief summary of major scientific contributions
Malaria
1. Discovered four new 8-aminoquinoline molecules synthesized at NIPER as broad-
spectrum antimalarials which showed activity better than chloroquine and primaquine in
blood-schizontocidal and met-hemoglobulin toxicity evaluations. Two international (1 US
and 1 European) patents have been granted on this work.
2. Reported that recombinant human interleukin-12 sterile-protected rhesus monkeys
(Macaca mulatta) from Plasmodium cynomolgi B sporozoite-induced malaria.
3. Discovered that purified human C-reactive protein (CRP) sterile-protected rhesus monkeys
(M. mulatta) against P. cynomolgi B sporozoite-induced malaria.
4. Discovered that recombinant mouse granulocyte-macrophage colony-stimulating factor
(GM-CSF) and methionine-enkephalin (M-ENK) or its fragment peptide Tyr-Tyr-Gly
protected mice against both sporozoite- and trophozoite-induced rodent malarias,
apparently via macrophage-mediated mechanisms which are, at least partly, nitric oxide-
dependent.
5. Developed a new rigorous rodent malaria vaccination model (P. yoelii nigeriensis/mouse)
to study mechanisms of protective immunity and to evaluate potential immunoadjuvants;
IL-1 fragment peptide 163-171 showed strong co-adjuvant activity with saponin.
6. Discovered M. assamensis and Presbytis entellus as the two new hosts of P. knowlesi.
7. Reported that an antigenic variant (W3) of P. knowlesi was relatively resistant to
chloroquine as compared to its parent strain (W1) in rhesus monkeys (M. mulatta); P.
falciparum antigenic variants also showed differences in their susceptibility to chloroquine,
in vitro.
Dr. Prati Pal Singh

10
8. Discovered a distinct dichotomy in the monoclonal antibodies (MAbs) generated from the
splenocytes of mice vaccinated with P. yoelii nigeriensis total parasite antigens soluble in
culture medium and saponin, based on their merozoite invasion inhibition and passive
transfer of protection activity.
9. Demonstrated that (1) probenecid (PB) is a blood-schizonticidal agent and (2) it synergizes
with both dapsone (DS) and proguanil (PG). A combination of all the three agents also
resulted in synergism, and reduced the required dose of DS, as compared to DS stand-alone
by 10.17-fold. This first report of the in vivo antimalarial activity of PB suggests that it can
be used as a new therapeutic agent to reduce dose-related toxicity of DS.
10. Developed a new experimental rodent model of cerebral malaria (P. yoelii nigeriensis
infection in Swiss mice.
Tuberculosis
1. Indo-European Union FP7 project: identified 34 new anti-tuberculosis (TB) compounds
as potential new drugs (IC99: 6.25 µg/ml) against Mycobacterium tuberculosis. Further,
12 compounds have been found active against an Indian M. tuberculosis clinical isolates
(resistant to isoniazid) at 6.25 µg/ml (IC99); apparently, two of them have the potential for
clinical testing.
2. Contributed extensively to the roles of innate immunity in TB, and discovered that (i)
purified mouse serum amyloid P-component (SAP, a pentraxin) significantly inhibited the
uptake of M. tuberculosis by mouse alveolar macrophages, in vitro, apparently through
mannose 6-phosphate (M6-P) receptors, and thus demonstrated M6-P receptors to be the
new type of receptors involved in the uptake of M. tuberculosis by macrophages, in vitro.
Further, discovered that purified mouse SAP activated alveolar macrophages to greatly
inhibit the intra-macrophage growth of M. tuberculosis, in vitro, apparently via nitric
oxide (NO)-dependent mechanism(s). All these original researches have greatly
contributed to our existing fundamental knowledge of TB, which are expected to help in
the discovery of new therapies for TB.
3. Discovered a new 5-nitroimidazole drug, satranidazole, to be active in an in vitro model
(Wayne model) of hypoxia-induced non-replicating persistent M. tuberculosis (latent
forms).
4. Developed a new short-term rodent model for the screening of potential anti-TB
compounds against M. smegmatis.
5. Demonstrated IL-6 as a potent biomarker of mycobacterial viability, virulence and
pathogenesis using cytokine multiplex systems and confocal microscopy. (In just last
18 months, our research paper on this work has 376 citations)
Acute-phase reactant biology

1. Reported that purified human CRP activated monkey macrophages for enhanced
phagocytosis of P. fragile-infected monkey erythrocytes, in vitro.
2. Discovered that purified human CRP induced increase in serum CSFs in monkeys (M.
mulatta) and stimulated monkey macrophages to elaborate CSFs, in vitro, and that
purified mouse SAP induced increase in serum CSFs in mice and stimulated mouse
macrophages to elaborate CSFs, in vitro.
3. Reported that spororzoite- and trophozoite-induced P. cynomolgi-infection in monkeys
induced increased production of serum CSFs. In vitro both intact P. cynomolgi-
infected monkey erythrocytes and their soluble components stimulated monkey
macrophages to produce CSFs, de novo. Similar results were obtained using P. berghei
and mice.
Dr. Prati Pal Singh
11
4. Studied the induction kinetics of SAP in various inbred and recombinant inbred Lr and
Ls mouse strains during Listeria monocytogenes infection. A strong correlation
between SAP levels and genetic control of host resistance to L. monocytogenes
infection was observed. In vitro, purified mouse SAP activated mouse macrophages
(peritoneal, BM-derived and subcutaneous) for the intracellular killing of L.
monocytogenes. Prof. Singh also reported several other immunoregulatory properties
of purified mouse SAP.
Neuroimmunomodulation
1. Discovered opiates as a new class of drugs which protected against malaria,
leishmaniasis and tuberculosis in rodents. Morphine in a dose-dependent manner,
biphasically modulated the course of P. berghei infection in mice; low doses provided
complete protection. Similarly, morphine protected both hamsters and mice infected
with Leishmaniasis donovani, in a macrophage-mediated and NO-dependent manner.
Further, morphine protected mice against M. tuberculosis H37Rv infection though
macrophage-mediated and NO-dependent mechanisms.
2. Reported that morphine, in a dose-dependent biphasic manner, modulated the
production of plasmodial antigens-induced production of CSFs by macrohpahes, in
vitro.
3. Reported that M-ENK and C.D.R.I. compound 82/205, modulated the elaboration of
CSFs by malarial antigens-stimulated macrophages, and of lymphokines (IFN- and
IL-4) by Con A-stimulated splenocytes; compound 82/205 was more potent.
4. Demonstrated that morphine, M-ENK, dermorphin and compounds 82/205 showed
high immunoadjuvant activity in a new rodent malaria (P. yoelii nigeriensis/mouse)
vaccination model.
Amoebiasis and trichomoniasis

1. Contributed extensively to the pre-clinical discovery/development of a new anti-
amoebic drug satranidazole, now on the market.
2. Developed a new model (Entamoeba muris/rat) for screening potential luminal
amoebcides.
3. Reported the anti-trichomonal activity of triclosan and nitazoxanide, separately, in
vitro.
TEACHING EXPERIENCE: (Jan. 1997 onwards)
Special attainments in education
For last nearly 16 years, I am involved in the teaching of biotechnology, microbiology,

parasitology, neuroimmunology and new drug discovery research to the students of
Pharmaceutical Sciences. For this, special courses addressing to our National and
International Health problems (Pharmaceutical Biotechnology and Pharmaceutical
Parasitology and Microbiology) have been developed for both Master’s and Ph. D.
students. The courses were well taken by the students and industries.
(a). Supervised/supervising the Ph. D. thesis work of the following students, and the
titles of their thesis are:
Dr. Prati Pal Singh

12
1. “Vaccination of mice against Plasmodium yoelii nigeriensis and

characterization of the protective monoclonal antibodies”. (Degree
awarded, 2002; SRF: CSIR).
2. “Experimental studies on neuroimmunomodulation in visceral
leishmaniasis”. (Degree awarded, 2004; JRF/SRF: CSIR, NET).
3. “Acute-phase reactants in murine tuberculosis: cellular and molecular
studies”. (Degree awarded, 2005; JRF/SRF: CSIR, NET).
4. “Bioimmunotherapy of rodent malarias: elucidation of cellular and
molecular mechanisms” (Degree awarded, 2007; JFR: CSIR, NET).
5. “Experimental immunological approaches to target tuberculosis” (Degree
awarded; JRF/SRF: CSIR, NET).
6. “Experimental Studies on Murine Cerebral Malaria” (thesis submitted
2018; NIPER fellowship).
7. “Studies on the protective effect(s) of vitamins on rodent malaria”
(continuing; DoP-funded NIPER fellowship).
8. “Immunomodulatory effects of lithium chloride during rodent malaria”
(continuing; NIPER fellowship).
9. “Chemotherapeutic and immunological studies on experimental visceral
leishmaniasis” (continuing; DoP-funded NIPER fellowship).
10. “Experimental studies on the pathogenesis of visceral leishmaniasis”
11. “Bioimmunotherapy of tuberculosis: co-treatment with recombinant mouse
granulocyte-macrophage colony-stimulating factor and met-enkephalin”
12. “Experimental immunotherapy for the treatment of tuberculosis”
Serial No. 1 student was registered under Biotechnology programme, the remaining nine
students were/are under Pharmacology and Toxicology programme.
(b). Total M. S. (Pharm.) students 68. Thirty, Master’s degree students have been
awarded their M. S. (Pharm.) Biotechnology (Sr. No. 1-4) and Pharmacology and
Toxicology (Sr. No. 5 and 62) degrees. The titles of their theses are:
1. “Molecular mechanisms in pathogenesis in malaria: role of colony-

stimulating factors”
2. “Vaccination of mice against Plasmodium yoelii nigeriensis”
3. “Plasmodium berghei infection in mice: serum amyloid P-component
response and its role in enhanced erythrophagocytosis”
4. “Morphine-induced immunomodulation in Plasmodium yoelii nigeriensis-
infected mice”
5. “Selection and cloning of artemisinin and artenilic acid resistant strains of
rodent malaria parasites”
6. “Neuroimmunomodulatory effects of morphine in murine tuberculosis”.
7. “Determination of blood-schizontocidal activity of macrolide antibiotics
against rodent malarias: stand alone and adjunct”
8. “Leishmania donovami infection in hamsters: chemotherapy and selection
of a miltefosine-resistant strain”
Dr. Prati Pal Singh
13
9. “Experimental studies on the efficacy of nitazoxanide against Trichomonas

vaginalis”
10. “Possible reduction of miltefosine curative doses by co-administration of
recombinant human granulocyte-macrophage colony-stimulating factor and
methionine-enkephalin: a rodent visceral leishmaniasis study”
13. “Allicin treatment of rodent malaria: stand alone and in combination with
curcumin and artemisinin”
14. “Evaluation of in vitro efficacy of satranidazole against Mycobacterium
tuberculosis in latent state under oxygen depletion conditions”
15. “Determination of the immunomodulatory effects of morphine on
experimental immunization using a rodent malaria vaccination model”
16. Trichomonas vaginalis: in vitro cloning and drug susceptibility testing”
17. “Evaluation and comparison of in vitro antimycobacterial activity of
satranidazole against nutrient starvation and hypoxia-induced latent
Mycobacterium tuberculosis”
18. “Evaluation of in vitro susceptibility of Trichomonas vaginalis to triclosan”
19. “Investigation of the effect of probenecid, proguanil and dapsone
combination against Plasmodium berghei infection in mice”
20. “Assessment of nelfinavir in Leishmania donovani-infected golden
hamsters”
21. “To investigate the antileishmanial effect of amiodarone against
Leishmania donovani infection in golden hamsters”
22. “To investigate the combination effect of miltefosine and 3,3’-di indolyl
methane against Leishmania donovani infection in hamsters”
23. To study the effect of atorvastatin on the antimalarial activity of artesunate
against Plasmodium yoelli nigeriensis infection in mice”
24. “Antimalarial activity assessment of farnesol in Plasmodium yoelli
nigeriensis infected in mice”
25. “Study of the effect of the combination of risedronate and azithromycin in
a rodent malaria model”
26. “To determine the antimalarial activity of the combination of azithromycin
and quinine in Plasmodium yoelii nigeriensis-infected mice”
27. “Experimental immunization of mice using Plasmodium yoelii nigeriensis
antigens”
28. “To determine the antimalarial effect of ibandronate against Plasmodium
berghei infection in mice”
29. “To determine the antimalarial activity of the combination of limonene and
farnesol in Plasmodium berghei-infected mice”
30. “To investigate the combined effect of omeprazole and amodiaquine in
Plasmodium berghei-infected mice”
31. “To investigate the therapeutic potential of LL-37 cationic antimicrobial
peptide in Plasmodium berghei-infected mice”
32. “To investigate the effect of deltrophin II in Plasmodium berghei-infected
mice”
33. “To determine the antimalarial effect of gramicidin in Plasmodium berghei-
infected mice”
34. “To determine the combined effect of chloroquine and [D-Ala2, D-Leu5]
enkephalin in Plasmodium berghei-infected mice”
Dr. Prati Pal Singh

14
35. “To determine the blood-schizonticidal activity of fenofibrate against

Plasmodium berghei infection in mice”
36. “To determine the blood-schizonticidal activity of thioridazine against
37. “To determine the blood-schizonticidal activity of fusidic acid against
38. “To determine the blood-schizonticidal activity of telithromycin against
Plasmodium berghei infection in Swiss mice”
39. “To determine the blood-schizonticidal activity of linolenic acid against
Plasmodium yoelii nigeriensis infection in Swiss mice”
40. “To determine the blood-schizonticidal activity of ellagic acid against
41. “To determine the blood-schizonticidal activity of clotrimazole in
Plasmodium yoelii nigeriensis-infected Swiss mice”
42. “To determine the blood-schizonticidal activity of fluconazole in
Plasmodium yoelii nigeriensis-infected Swiss mice”
43. “To determine the blood-schizonticidal activity of quinacrine against
44. “To determine the effect of artesunate on the phagocytosis P. berghei-
infected erythrocytes by mouse peritoneal macrophases, in vitro”
45. “Determination of the role of IL-18 in the pathogenesis of rodent malaria”
46. “To determine the blood-schizonticidal activity of bafilomycin against
P.berghei infection in Swiss mice”
47. “To determine the dapsone dose reduction potential of probenecid in a
combination of dapsone and proguanil: a rodent malaria study”
48. “To determine the blood-schizonticidal activity of a combination of
linolenic acid and linoleic acid in P. berghei-infected Swiss mice”
49. “To determine the blood-schizonticidal activity of a combination of 5-
fluoroorotate and pyrimethamine against P. yoelii nigeriensis-infection in
Swiss mice”
50. “To determine the effect of chloroquine on the P.berghei antigen-induced
elaboration of colony-stimulating factors by macrophages, in vitro”
51. “To determine the effect of curcumin on the P. berghei antigen-induced
elaboration of colony-stimulating factors by macrophages, in vitro”
52. “To determine the blood-schizonticidal activity of thiostrepton against P.
yoelii nigeriensis infection in Swiss mice”
53. “NIPER compounds NP-3524, NP-3525, NP-3526 and NP-3527 belonging
to artemisinin class: determination of their blood-schizonticidal activity in
54. “Protection of mice from malaria: co-treatment with rmGM-CSF and [D-
Ala2, D-Leu5] encephalin”
55. “Study of blood schizonticidal activity of NIPER compounds: NP 2818, NP
2819, NP 2825, NP 2830 and NP 2832 against P. berhei infection in Swiss
mice”
56. “To determine the combined effect of clarithromycin and [D-Ala2, D-Leu5]
enkephalin against malaria caused by Plasmodium berghei in mice”
57. “To determine the effect of [D-Ala2, D-Leu5] encephalin on the
phagocytosis of Plasmodium berghei-infected erythrocytes, in vitro”
Dr. Prati Pal Singh

15
58. “Determination of the effect of L-valine on the phagocytosis of Plasmodium

berghei-infected erythrocytes, in-vitro”
59. “Determination of the effect of novobiocin on the course of Plasmodium
berghei infection in Swiss mice”
60. “Evaluation of the blood-schizonotocidal activity of chlorpheniramine in
61. “Determination of the effect of mycophenolic acid on the course of
62. “Determination of the effect of zaprinast on the course of Plasmodium
63. “Determination of the effect of salinomycin on the course of Plasmodium
64. “Determination of the effect of noecuproine on the course of Plasmodium
65. “Determination of the stand-alone and combined effects of nerolidol and
limonene on the course of Plasmodium yoelii nigeriensis infection in Swiss
mice”
66. “Determination of the effect of anisomysin on the course of Plasmodium
yoelii nigeriensis infection in Swiss mice”
67. “Determination of the stand-alone and combined effects of L-valine and L-
arginine on the phagocytosis of P. berghei-infected erythrocytes in vitro and
immunomodulatory activity in Swiss mice”
68. “Determination of the effect of epigallocatechin gallate on the course of
(c). Supervised the Summer Training Programme work of M. Sc. (Microbiology and
Biotechnology) students from Panjab University, Chandigarh; Kurukshetra
University, Kurukshetra and Banasthali Viday Peeth, Banasthali. The titles of their
projects are:
1. Hybridoma technology: maintenance of myeloma cell line and a hybrid.

2. Cultivation of mouse bone-marrow cells and the determination of
colony-stimulating factors.
3. Vaccination against rodent malaria.
4. Mouse splenic macrophages: cultivation and determination of
phagocytic activity.
5. Production of phagocytosis promoting lymphokines.
6. Hybridoma technology: maintenance of myeloma cell lines and
production of a hybrid.
7. Determination of rosette formation during Plasmodium yoelii nigeriensis
infection in mice.
8. Detection of antimalarial antibody by enzyme-linked immunosorbant
assay.
9. Fluorescence microscopy of malaria parasites.
10. Mycobacteria-macrophage interaction.
11. Vaccination against P. yoelii nigeriensis: antigen preparation, protein
estimation, immunization and assessment of protection.
12. Chemotherapy and drug resistance in malaria: a rodent model.
Dr. Prati Pal Singh
16
(d). Taught the following Courses to M. S. (Pharm.) and Ph. D. students:

1. BT-510 (Biotechnology in Pharmaceutical Sciences)
2. BT-511 (Immunochemical/Radiochemical Methods of Analysis)
3. BT-630 (Immunology and Immunotechnology)
4. BT-640 (Applied Microbiology and Fermentation Technology)
5. BT-650 (Diagnostics)
6. PC-540 (Chemotherapy of Parasitic and Microbial Infections)
7. PC-611 (Pharmacological Screening)
8. PC-660 (Chemotherapy and Immunopharmacology)
9. BT/PC-720 (Ph. D. course: Application of Biotechnology in Parasitic
Disease Research).
10.BT/ PC-740 (Ph. D. course: Cellular and Molecular Parasitology)
11. PC-830 (Ph.D. course: Parasitology/Microbiology, community and
Pharmacy.
12. Laboratory practical.
13. Seminars
Course coordinator: BT-510, BT-511, BT-630, BT-640, BT-650, GE-511, PC-540,

BT/PC-720, PC-740 and PC-830.
Examiner of Ph. D. theses
1. “Modulation of Host Cell Interactomics by Intracellular Pathogen Leishmania

donovani”. (2015). Dept. of Life Sciences, Jawaharlal Nehru University, New
Delhi.
2. “Investigation of the role of zinc in hypobaric hypoxia induced memory
impairment and neuronal damage”. (2011). ACBR, University of Delhi, Delhi.
3. “Modes of action and mechanisms of resistance to promomycin in visceral
leishmaniasis”. (2009). Dept. of Life Sciences, Jawaharlal Nehru University,
New Delhi.
4. “Studies on phytochemical and pharmacological activity Scoparia dulcis Linn”.
(2008). Institute of Pharmacy, Bundelkhand University, Jhansi.
5. “Characterization and conformational studies of high mobility group box
(HMGB) proteins of Plasmodium falciparum”. (2008). Dept. of Biosciences,
Jamia Millia Islamia, New Delhi.
6. “Studies on glutathione reductase and thioredoxine reductase of Plasmodium
berghei”. (2007), Dept. of Biosciences, Himachal Pradesh University, Shimla.
7. “Cloning, expression, purification and immunization studies of MSP-1 19 and
MSP-1 42 (vaccine candidate antigens) of Plasmodium falciparum and P.
vivax”, (2006). Dept. of Zoology, University of Delhi, Delhi. Also, the
examiner to conduct the viva voce of this student.
8. “Isolation and characterization of some antigens of Plasmodium berghei”. (2006).
Dept. of Biosciences, Himachal Pradesh University, Shimla. Also, the examiner
to conduct the viva voce of this student.
9. “Detoxification of heme by Plasmodium falciparum histdine-rich proteins and its
inhibition by quinoline antimalarial drugs”. (2003). Dept. of Zoology, University
of Delhi, Delhi.
Dr. Prati Pal Singh

17
10. “Selection of antimalarial resistant lines of Plasmodium yoelii and sporogonic

studies in Anopheles stephensi”. (2003). Dept. of Zoology, University of Delhi,
Delhi.
11. “Synthesis, characterization and pharmacological evaluation of some novel
derivatives of hydrazones, chalcones and mannich bases” (2017). Faculty of
Pharmacy, Jawaharlal Nehru Technological University: Kakinada, Kakinada.
12. “To identify the new antibacterial agents targeting the M. tuberculosis ATP
synthase enzyme” (2017). Biological Sciences, Academy of Scientific and
Innovation Research. Clinical Microbiology Division, Institute of Integrative
Medicine, Jammu.
13. “Pharmacognostic and Pharmacological Investigations on Selected Indian
Medicinal Plants” (2018). Faculty of Pharmacy, Jawaharlal Nehru
Technological University: Kakinada, Kakinada.
Examiner of M. Sc. thesis
1. “Effect of cigarette smoke inhalation and/or α-tocopherol on pulmonary lipid

peroxidation and DNA freagmentation in male BALB/c mice”, 2001, Dept.
of Biophysics, Panjab University, Chandigarh.
Human resource development activities (recognition/honor/award received by P.G./Ph.

D. scholars ):
A. One Ph. D. student was selected for “First Winter School in Immunology in
India”, organized by Dr. V. S. Kanury Rao, International Center for Genetic
Engineering and Biotechnology at Kovalam, Kerala from Feb. 8-13, 2001.
B. One Ph. D. student was awarded a Travel Grant by CSIR, New Delhi, to present
an oral paper at UK. The Organizers waived the Registration fee.
C. One Ph. D. student has been awarded a Post-doctoral Fellowship in USA.
D. Three Ph. D. students were selected (and participated) in two different
International Training programmes in India. They were provided full financial
support.
E. One Ph. D. student has joined as Lecturer at the Dept. of Microbiology, Guru
Nanak Dev University, Amritsar, Punjab.
F. Two Ph. D. students have been appointed Scientists in two different National
Pharmaceutical Industries.
G. Seven P.G. students have joined scientific positions in National Pharmaceutical
Industries.
H. One foreign P.G. student has done master’s degree work on malaria and is
working as a lecturer in Ethiopia.
I. One Ph. D. student has been awarded DBT fellowship to work on tuberculosis in
Seattle, Washington, USA.
PRODUCTS DEVELOPED:
Dr. Prati Pal Singh

18
1. Anti-Plasmodium yoelli nigeriensis monoclonal antibodies. (For details please see

product section “Monoclonal Antibodies” in Hybridoma and Hybridomics, 2003,
Vol. 22 (3), 61)
2. Was involved in the pre-clinical development of anti-amoebic drug satranidazole,
now on the market.
3. Identified four novel 8-aminoquinolines as broad spectrum antimalarias in rodent
malaria models and P. falciparum, in vitro. These compounds have been synthesized
at NIPER and have been patented. Their evaluation in non-human primate malarias
is being persued.
4. As part of the ongoing Indo-European Union FP7 funded project titled “New
Approaches to Target Tuberculosis”, identified 34 compounds to be active against
Mycobacterium tuberculosis H37Rv (by BACTEC 460 method) at 6.25
µg/mL(IC99). Six of these compounds have shown MIC values of ≤ 0.39 µg/ml.
5. Dapsone (DS)-chlorproguanil combination (Lapdap™), though effective against

human malaria parasite Plasmodium falciparum, has been reported to reduce
hemoglobin concentration in patients with glucose-6-phosphate dehydrogenase
deficiency due to dose-related toxicity of DS component. We have observed that (1)
probenecid (PB) is a blood-schizonticidal agent and (2) it synergizes with both DS
and proguanil (PG). A combination of all the three agents also resulted in synergism,
and reduced the required dose of DS, as compared to DS stand-alone, by 10.17-fold.
This first report of the in vivo antimalarial activity of PB suggests that it can be used
as a new therapeutic agent to reduce dose-related toxicity of DS.
6. Triclosan, at 50 µg/ml (minimal inhibitory concentration; MIC), was observed to be

active against both the metronidazole-sensitive and -resistant strains of T. vaginalis,
in vitro; the MICs of metronidazole against both these strains was 1.6 µg/ml and 4.8
µg/ml, respectively. The results of this first study demonstrate that triclosan may be
a promising potential agent for the treatment and management of human
trichomoniasis.
CONCEPTS CREATED
1. Bioimmunotherapy of malaria using rmGM CSF and met-enkephalin co-treatment.

2. Opioids as potential drugs for the treatment of microbial and parasitic diseases.
3. Generation of a qualitatively distinct dichotomous immune response to malaria in
vaccinated/protected mice, which probably ensued in the generation of MAbs with
functional heterogeneity.
4. Involvement of macrophage mannose 6-phosphate receptors in the uptake of
Mycobecterium tuberculosis.
5. Role of pentraxins in host defense from tuberculosis.
6. IL-6 has been identified as a potent biomarker of mycobacterial infections.
PROCESSES/MODELS/METHODOLGY/TECHNOLGY DEVELOPED
1. Developed a new rodent model for the screening of potential luminal amoebicides.
2. Developed a new rodent malaria (P. yoelli nigeriensis /mouse) vaccination model. As
this parasite causes a fulminating 100% lethal infection in mouse, vaccination-
induced protective immunity can be very clearly distinguished from slow-grade
infection- induced immunity.
Dr. Prati Pal Singh
19
3. Antigen-induced production of CSFs by macrophages in vitro, as a model for the

biological evaluation of potential immunomodulators. Extensive publication in high-
impact journals have been made on this new model.
4. Developed a new experimental rodent model of cerebral malaria (P. yoelli nigeriensis
infection in Swiss mice).
NATIONAL RESEARCH PROJECTS

1. Determination of possible linkage between antigenic variation and drug-resistance in
Plasmodium falciparum, in vitro. CSIR, New Delhi. (PI; Mar. 2000 – Feb. 2003; Rs.
10.53 lakh)
2. Bioimmunotherapy of rodent malaria: evaluation of recombinant granulocyte-
macrophage colony-stimulating factor and methionine-enkephalin co-treatment. DBT,
New Delhi. (P I; Mar. 2003 – Feb. 2006; Rs. 20.12 lakh)
3. Acute-phase reactants during Mycobacterium tuberculosis H37Rv infection in mice:
induction kinetics, and their role(s) in immunoregulation and host-defense. ICMR,
New Delhi. (P I; Jan. 2004 – Dec. 2006; Rs. 10.77 lakh)
4. Hybridomic elucidation and molecular characterization of antimalarial immune
response: a rodent model. CSIR, New Delhi. (PI; Apr. 2009 – Mar. 2012; Rs. 21.65
lakh).
5. Got Rs. 903 lakh (Rs. 90.3 million) for a five year proposal submitted (Rs. 12. 44
crore; Rs. 124.4 million) to the Ministry of Chemicals and Fertilizers, Government of
India, for XI Five Year Plan (2007-2012) to start a new Department of Pharmaceutical
Parasitology and to expand and modernize the existing small base of pharmaceutical
parasitology research and education at NIPER.
6. I am one of the two PIs of a project “Studies on molecular approaches to TB:
determination of prevalence of MDR and XDR strains, drug susceptibility testing and
development of new diagnostic tools” funded from the Department of Pharmaceuticals,
Ministry of Chemicals and Fertilizers, Government of India. (Total project grant Rs.
194 lakh; 2013-2016)
7. I am one of the six PIs of “A Program Project For Target Specific New Drug Discovery
of Anti-tubercular Agents” at NIPER, S. A. S. Nagar that has been funded for three
years (2013-2015) by the Department of Pharmaceuticals, Ministry of Chemicals and
Fertilizers, Government of India. (Rs. 4,88.00 lakh)
8. I am one of the PIs of “A Program project For Target Specific New Drug Discovery
Research Against Kala-azar” at NIPER, S. A. S. Nagar has been funded for three years
(2013-2015) by the Department of Pharmaceuticals, Ministry of Chemicals and
Fertilizers, Government of India. (Rs. 4,88.00 lakh)
9. I am one of the two PIs of a project “New Biotherapeutic Approached to the Treatment
of Tuberculosis” funded from the Department of Pharmaceuticals, Ministry of
Chemicals and Fertilizers, Government of India. (Total project grant Rs. 243.84 lakh;
2016-2019)
INTERNATIONAL RESEARCH PROJECT
1. Indo-European Union Seventh Framework Programme (FP7). Project titled “New

Approaches to Target Tuberculosis” was funded (total funding: Euro 29, 94, 478.00)
in collaboration with Dr. Piet Herdewijn (Coordinator; K. U. Leuven, Belgium), Dr. S.
Dr. Prati Pal Singh
20
H. E. Kaufmann (Max-Planck Institute for Infection Biology, Germany; Dr. Marino

Zerial (Max-Planck Institute of Cell Biology and Genetics, Germany), Dr. Elaine Davis
(Div. of Mycobacterial Research, National Institute for Medical Research, UK), Dr.
Matthias Wilmanns (EMBL, Germany), Prof. Jyoti Chattopadhayay (Bioorganic
Chemisitry Dept., Uppsala University, Sweden), Prof. Prati Pal Singh (National
Institute of Pharmaceutical Education and Research, Mohali; Rs. 84 lakh), Dr. Rajesh
Gokhale (National Institute of Immunology, India) and Dr. Ram Upadhayaya (Institute
of Molecular Medicine, Pune). The project was operational Oct. 01, 2008-Sept. 30,
2011.
2. A no cost project (with Prof. Branka Zorc, Zagreb, Croatia) on the screening of
potential antimalarial compounds is operational for last 02 years. Nearly 50
compounds have been tested. Out of this work, one paper has been communicated for
publication and the other shall be sent soon.
3. A collaborative research programme with Prof. Drik Schluter, Otto-van Guericke

Univ., Magdeburg, Germany, has been initiated for the development of a new rodent
cerebral malaria model using KO mice. The agreement is expected to be signed shortly.
INVITED LECTURES: Sixty two; SCIENTIFC SESSIONS CHAIERD: Thirty eight

KEYNOTE ADDRESS: Twelve; BOOK REVIEWED: Eighteen
INDUSTRY ASSOCIATIONS: Technical Services Agreements with two
pharmaceutical companies viz. M/s. Institute of Molecular Medicine, Kolkata and M/s.
Advanced Enzyme Technologies Limited, Thane, are operational. Agreements with two
more industries are being negotiated and will be signed, soon.
PATENTS (granted; including US, one, Europe, one)
1. Jain, R.; Jain, M.; Singh, P. P.; Singh, S.; Sachdeva, S.; Misra, V.; Ramarao, P.; Kaul,
C. L.; Tikoo, K. Ring-substituted 8-aminoquinoline analogs as antimalarial agents and
process for their preparation. European Patent No. EP1606263, WO 2004085402,
dated 21/12/2005, Appl. No. PCT/IB03/06362, filed 15/12/2003, 62 pp.
process for their preparation. US Patent No. 6,979,740, Dec 27, 2005, 18 pp.
process for their preparation. Australian Patent No. AU2003292489A1, dated
18/10/2004, Appl. No. AU2003-292489, dated 22/12/2003.
process for their preparation. Brazilian Patent No. BR2003018214A, dated 21/3/2006,
Appl. No. BR0318214-2, dated 22/12/2003.
Dr. Prati Pal Singh
21
process for their preparation. Japanese Patent No. JP2006521284T, dated 21/9/2006,
Appl. No. JP2004-569883, dated 22/12/2003.
6. Jain, R.; Jain, M.; Singh, P. P.; Singh, S.; Sachdeva, S.; Misra, V.; RamaRao, P.; Kaul,
C. L. Ring-substituted 8-aminoquinoline analogues as antimalarial agents. 2003,
Indian Patent No. IN2003DE00459, dated 9/3/2007, Appl. No. 459/DEL/2003, dated
27/3/2003.
7. Jain, R.; Jain, M.; Singh, P. P.; Singh, S.; Sachdeva, S.; Misra, V.; RamaRao, P.; Kaul,
C. L. A process for preparation of ring-substituted 8-aminoquinoline analogues as
antimalarial agents. 2003, Indian Patent No. IN 234308, dated 19/6/2009, Appl. No.
IN2003DE00473, dated 27/3/2003.
8. Jain, R.; Suryanarayana V.; Singh, P. P.; Kinhikar, A. G.; Singh, S.; Jain, M.;
Sachdeva, S.; Misra, V.; Ramarao, P.; Kaul, C. L. Quinoline analogues with broad-
spectrum of antimalarial activities (Novel 4-ethyl-5-alkoxyprimaquine compounds).
2011, Indian Patent no. IN 248025 dated 9/6/2011, Appl. No. IN2002DE01112
A2005031.
Filed
9. Jain, R.; Balasubramanian V.; Nayyar, A.; Palde, P. B.; Jain, M.; Sachdeva, S.; Kaur,
S.; Misra, V.; Singh, P. P.; Kaul, C. L. Ring-substituted quinolines as anti-tuberculosis
agents. Indian Pat. Appl. 2005, CODEN: INXXBQ IN 2002DE00628 A 20050311
AN 2007:299982.
Publications: (total 233; research papers, 99; abstracts, 129; editorials, 05; in reverse
chronological order).
 This research paper featured on World Biomedical Frontiers, because of its

innovation and potential for significant impact; Ref. No. 9.
 This research paper published in NatureIndia as a research highlight titled “A
shot of morphine to treat TB”; doi:10.1038/nindia.2008.110; published online
31 January 2008; Ref. No. 30.
 This research paper has 2724 citations since Dec. 21, 2013; Ref. No. 12.
 This research paper published in Nature Medicine; Ref. No. 67.
1. Sinha, Sanjeev; Gupta, Kartik; Kohli, Mikashmi; Myneedu, VP, Pandey, RM and
Singh, Prati Pal (2018) Prevalence of multi-drug resistant tuberculosis among new
culture-positive pulmonary tuberculosis patients in tertiary care centre of North
India. J. Tuberc. Ther. 3, 1000116.
2. Jain, Meenakshi; Reddy, C. V. Ravi P., Halder, Moumita; Singh, Savita; Kumar,
Randheer; Wasudeo, Sagar Gajbe; Singh, Prati Pal; Khan, Shabana I., Jacob,
Melissa R., Tekwani, Babu Land Rahul Jain (2018) Synthesis and Biological
Evaluation of 8‑Quinolinamines and Their Amino Acid Conjugates as Broad-
Spectrum Anti-infectives. ACS Omega 3, 3060-3075.
Dr. Prati Pal Singh

22
3. Singh, Prat Pal and Prakash, Bhanu (2017) Pathogenesis and experimental models
of cerebral malaria. J. Pharm. Microbiol. 3, 1-12.
4. Bhagat, S., Arfeen, M., Adane, L., Singh, S., Singh, Prat Pal, Chakraborti, A. K.,
Bharatam, P. V. (2017) Guanylthiourea derivatives as potential antimalarial agents:
Synthesis, in vivo and molecular modelling study. Eu. J. Med. Chem. 135, 339-
348.
5. Singh, Prati Pal and Goyal, A. (2016) Macrophage-mycobacteria interaction:

exploration of proteomic signatures. J. Anal. Pharm. Res. 2 (4),
00025.DOI:10.15406/japlr.2016.02.00025.
6. Singh, Prati Pal and Chakraborty, P. (2016) Malaria: autophagy as a potential

therapeutic target. J. Pharm. Pharmacol. 4, 298-306.
7. Tesfaye, Solomon; Prakash, Bhanu and Singh, Prati Pal (2015) Apicoplast
Biosynthetic Pathways as Possible Targets for Combination Therapy of Malaria. J.
Pharm. Pharmacol. 3, 101-115. (IF 2014: 2.264)
8. Singh, Prati Pal, Prakash, Bhanu and Yadaigiri, Ganesh (2015). Water related
diseases and their management. In “Major Tropical Diseases: Public Health
Perspective”. (Eds.) Aswani Kumar, Savio Rodrigues and Amit Das. Broadway
Publishing House, India.
9. Singh, Prati Pal and Prakash, Bhanu (2014). The dichotomy (generation of MAbs
with functional heterogeneity) in antimalarial immune response in
vaccinated/protected mice; a new concept in our understanding of protective
immune mechanisms in malaria. Human Vaccines & Immunotherapeutics, 10, 1-5.
(IF 2012: 3.136)
10. Jhamb, S. S., Goyal, Amit and Singh, Prati Pal (2014). Determination of the
activity of standard anti-TB drugs against intramacrophage Mycobacterium
tuberculosis, in vitro: MGIT 960 as a viable alternative for BACTEC 460. Brazilian
J. Infect. Dis. 18, 336-340.
11. Singh, Prati Pal and Galhotra, Abhiruchi (2014). Water, amoebiasis and public
health. In “Water and Health”. (Eds.) Prati Pal Singh and V. P. Sharma. Springer
India. pp 169-177.
12. Singh, Prati Pal and Goyal, Amit (2013). Interleukin-6: a potent biomarker of
mycobacterial infection. SpringerPlus. 2, 686-693.(Citations 2724 since Dec.
2013)
13. Patel, Kamlesh, Jhamb, S. S. and Singh, Prati Pal (2013). Metabolic changes in
Mycobacterium tuberculosis during nutrient starvation conditions. Int. J. Pharm.
Bio. Sci. 4, 229-239.
14. Kaur, Kirandeep., Jain, Meenakshi., Khan, S. I., Jacob, M. R., Tekwani, B. L.,
Singh, Savita., Singh, Prati Pal and Jain Rahul (2012). Amino acid, dipeptide and
Dr. Prati Pal Singh
23
pseudodipeptide conjugates of ring substituted 8-aminoquinolines: Synthesis and

evaluation of anti-infective, β-haematin inhibition and cytotoxic activities.
European J. Med. Chem. 52, 230-241. (IF 2011: 3.509)
15. Kaur, Kirandeep., Jain, Meenakshi., Khan, S. I., Jacob, M. R., Tekwani, B. L.,
Singh, Savita., Singh, Prati Pal and Jain Rahul (2011). Extended side chain
analogues of 8-aminoquinolines: snthesis and evaluation of antiprotozoal,
antimicrobial, bhematin inhibition, and cytotoxic activities. Med. Chem. Commun.
2, 300-307. (IF 2011: 1.271)
16. Kaur, Kirandeep., Jain, Meenakshi., Khan, S.I., Jacob, M.R., Tekwani, B. L.,
Singh, Savita., Singh, Prati Pal and Jain Rahul (2011). Synthesis, antiprotozoal,
antimicrobial, b-hematian inhibition, cytotoxicity and methemobglobin (metHb)
formation activities of bis (8-aminoquinolines). Bioorg. Med. Chem. 19, 197-210.
(IF 2011: 3.157)
17. S, Kharatmal., Jhamb, Sarbjit Singh and Singh, Prati Pal (2011). New insights into
latent tuberculosis: a persisting global health challenge. Int. J. Pharm. Sci. Res. 2,
1875-1887.
18. Patel Kamlesh, Sarbjit Singh, Singh, Prati Pal (2011). Models of latent
tuberculosis: their salient features, limitations and development. J. Lab. Physicians
3, 75-79.
19. Singh, Raman Preet., Jhamb, Sarbjit Singh, Singh, Prati Pal (2011). Evaluation of
antibiotic supplements for culturing Mycobacterium tuberculosis from mouse
macrophages and organs. Res. J. Pharma. Biol. Chem. Sci. 2, 370-377.
20. Chaudhari, Hemantkumar Somabhai and Singh, Prati Pal (2010). Comparative
drug susceptibility study of five clonal strains of Trichomonas vaginalis in vitro.
Asian Pacific J. Trop. Med.4, 50-53.
21. Jhamb, Sarbjit Singh and Singh, Prati Pal (2009). A short-term model for
preliminary screening of potential antituberculous compounds. Scand. J. Infect.
Dis.41, 886-889. (IF 2008: 1.678)
22. Singh, Ramanpreet; Jhamb, Sarbjit Singh and Singh, Prati Pal (2009). Effect of
morphine in Mycobaterium smegmatis infection in mice and macrophages. Ind. J.
Microbiol. 49, 276-282.
23. S, Kharatmal., Jhamb, Sarbjit Singh and Singh, Prati Pal (2009). Evaluation of
BACTEC 460 TB system for rapid in vitro screening of drugs against latent state
Mycobacterium tuberculosis H37Rv under hypoxia conditions. J. Microbiol.
Methods 78, 161-164. (IF 2008: 2.000)
24. Rajic, Z., Kos, G., Zorc, B., Singh, Prati Pal and Singh, Savita (2009).
Macromolecular pro-drugs. XII. Primaquine conjugates: Synthesis and preliminary
antimalarial evaluation. Acta Pharmaceutica 59, 107-115.
25. Singh, Prati Pal and Nagpal, Trinity (2009). Colony-stimulating factors and
malaria. In “Proceedings of National Academy of Sciences, India. Section-B,
Volume 79 (Spl. Issue) “Human Parasitic Infections of Pharmaceutical and
Dr. Prati Pal Singh
24
National Health Importance”. (Eds.) Prati Pal Singh and V. P. Sharma. NASI,
Allahabad, pp. 99-110.
26. Singh, Prati Pal and Nagpal, Trinity (2009). Neuroimmunomodulation and
infectious diseases. In “Proceedings of International Conference on
Neuroimmunomodulation and Infectious Diseases”, (Eds.) Prati Pal Singh and
Robert M. Donahoe, NIPER, S. A. S. Nagar, pp. 321-342.
27. Butani, Manoj and Singh, Prati Pal (2008). In vitro activity of triclosan against
metronidazole-sensitive and -resistant strains of Trichomonas vaginalis. J. Parasit.
Dis. 32, 111-117.
28. Jhamb, Sarbjit Singh; Singh, Raman Preet and Singh, Prati Pal (2008). A
comparision of conventional and radiometric methods for the assessment of anti-
tubercular activity of drugs against Mycobacterium tuberculosis in mouse and
macrophage models. Ind. J. Tuberculosis 55, 70-76.
29. Singh, Ramanpreet; Jhamb, Sarbjit Singh and Singh, Prati Pal (2008).
Iummnoenhancing effects of morphine during murine tuberculosis. In
“Proceedings of International Conference on Opportunistic Pathogens in AIDS”,
pp 110-115.
30. Singh, Raman Preet; Jhamb, Sarbjit Singh and Singh, Prati Pal (2008). Effects of
morphine during Mycobacterium tuberculosis H37Rv infection in mice. Life Sci.
82, 308-314. (IF 2007: 2.348)
31. Singh, Prati Pal and H. Jain (2007). Trichomoniasis: chemotherapy, drug
resistance and new targets. J. Parasit. Dis. 31, 79-91.
32. Singh, Prati Pal and Singal, Priya (2007). Morphine-induced

neuroimmunomodulation in murine visceral leishmaniasis: the role(s) of cytokines
and nitric oxide. J. Neuroimmune. Pharmacol. 2, 338-351.
(IF 2004: 3.319)
33. Singh, Prati Pal and Kaur, Sukhraj (2006). Serum amyloid P-component in murine
tuberculosis: induction kinetics and intramacrophage Mycobacterium tuberculosis
growth inhibition, in vitro. Microb. Infect. 8, 541-551.
(IF 2004: 3.753)
34. Singh, Prati Pal (2006). Malaria and macrophages: cellular and molecular basis of
pathogenesis and immune protection. J. Parasit. Dis. 30, 116-124.
35. Kaur, Amanpreet and Singh, Prati Pal (2005). Plasmodium chabaudi chabaudi AS
infection in mice: role(s) of erythrophagocytosis and nitric oxide in parasite
clearance. J. Parasit. Dis. 29, 112-118.
36. Singh, Prati Pal and Kaur, Sukhraj (2005). Acute-phase reactants during murine
tuberculosis: unknown dimensions and new frontiers. Tuberculosis, 85, 303-315.
(IF 2004: 1.935)
Dr. Prati Pal Singh

25
37. Jain, Meenakshi; Khan, Shabana I; Tekwani, Babu L; Jacob, Melissa R; Singh,
Savita; Singh, Prati Pal and Jain, Rahul (2005). Synthesis, antimalarial,
antileishmainal and antimicrobial activities of some 8-quinolinamine analogues.
Bioorg. Med. Chem. 13, 4458-4466. (IF 2003: 2.185)
38. Singal, Priya and Singh, Prati Pal (2005). Leishmania donovani amastigote
component-induced colony-stimulating factors production by macrophages:
modulation by morphine. Microb. Infect. 7, 148-156. (IF 2004: 3.753)
39. P. Singal and Singh, P. P. (2005). Leishmania donovani amastigote components-

induced colony-stimulating factors production. Parasitol. Int. 54, 9-20.
(IF 2003: 1.205)
40. Singal, P. and Singh, Prati Pal (2005). Morphine-induced nitric oxide-dependent
neuroimmunomodulation in established systemic Leishmania donovani infection in
hamsters. J. Parasit. Dis. 29, 29-40.
41. Kaur, Sukhraj and Singh, Prati Pal (2004). High output expression of colony-
stimulating factors by 30-kDa antigen of Mycobacterium tuberculosis. In
Tuberculosis: Current Research Trends (Ed. Pawan Sharma). Proceedings of the
"International Symposium on Emerging Trends in Tuberculosis Research", pp.
159-173.
42. Monga, Vikramdeep; Nayyar, Amit; Vaitilingam, Balasubramanian; Palde,

Prakash B; Jhamb, Sarbjit Singh; Kaur, Sukhraj; Singh, Prati Pal and Jain, Rahul
(2004). Ring-substituted quinolines. Part 2: Synthesis and antimycobacterial
activities of ring-substituted quinolinecarbohydrazide and ring-substituted
quinolinecarboxamide analogues. Bioorg. Med. Chem. 12, 6465-6472.
(IF 2003: 2.185)
43. Kaur, Sukhraj; Kaur, Harsimrat and Singh, Prati Pal (2004). Induction of colony-
stimulating factors by a 30-kDa secretory protein of Mycobacterium tuberculosis
H37Rv. Eur. Cytokine Ntw. 15, 327-338. (IF 2002: 2.153)
44. Vaitilingam, Balasubramanian; Nayyar, Amit; Palade, Prakash. B., Monga,

Vikramdeep; Jain, Rahul; Kaur, Sukhraj and Singh, Prati Pal (2004). Synthesis
and antimycobacterial activities of ring-substituted quinolinecarboxilic acid/ester
analogues. Prat 1. Bioorg. Med. Chem. 12, 4197-4188. (IF 2003: 2.185)
45. Kaur, Sukhraj and Singh, Prati Pal (2004). Serum amyloid P-component-mediated
inhibition of the uptake of Mycobacterium tuberculosis by macrophages, in vitro.
Scand. J. Immunol. 59, 425-431. (IF 2003: 1.942)
46. Vangapandu , Suryanarayana; Jain, Meenakshi; Jain, Rahul; Kaur, Sukhraj and
Singh, Prati Pal (2004). Ring-substituted quinolines as potential anti-tuberculosis
agents. Bioorg. Med. Chem. 12, 2501-2508. (IF 2003: 2.185)
47. Kaur, A., Kinhikar, A. G. and Singh, Prati Pal (2004). Bioimmunotherapy of
rodent malaria: co-treatment with recombinant granulocyte-macrophage colony-
Dr. Prati Pal Singh
26
stimulating factor and an enkephalin fragment peptide Tyr-Gly-Gly. Act. Trop. 91,
27-41. (IF 2003: 1.336)
48. Suryanarayana, V., Sachdeva, S., Jain, M., Savita, Singh; Singh, Prati Pal, Kaul,
Chaman Lal and Jain, Rahul (2004). 8-Quinolinamines conjugated with amino
acids are exhibiting potent blood-schizontocidal antimalarial activities. Bioorg.
Med. Chem. 12, 239-247. (IF 2003: 2.185)
49. Jain, M., Suryanarayana, V., Sachdeva, S., Singh Savita; Singh, Prati P., Gena,
Gopa B., Tikko, K., Ramarao, P., Kaul, Chaman and Jain, R (2004). Discovery of
a bulky 2-tert-butyl group containing primaquine analogue that exhibits potent
blood-schizontocidal antimalarial activities and complete elimination of
methemoglobin toxicity. J. Med. Chem. 47, 285-287. (IF 2003: 4.82)
50. Singal, P. and Singh, Prati Pal (2003). Induction of colony-stimulating factors by
Leishmania donovani amastigote soluble antigens. J. Parasit. Dis. 27, 85-93.
51. Suryanarayana, V., Sachdeva, S., Jain, M., Savita, Singh; Singh, Prati Pal, Kaul,
Chaman Lal and Jain, Rahul (2003). 8-Quinolinamines and their pro prodrug
conjugates as potent blood-schizontocidal antimalarial agents. Bioorg. Med. Chem.
11, 4557-4568. (IF 2003: 2.185)
52. Singal, Priya and Singh, Prati Pal (2003). Cellular and Cytokine Responses in
Leishmaniasis: A Review. J. Parasit. Dis. 27, 1-12.
53. Singal, Priya and Singh, Prati Pal (2003). C-reactive protein-mediated enhanced
uptake of Leishmania donovani amastigotes by mouse macrophages in vitro. In
Parasites and Diseases (Eds. Neelima Gupta and D. K. Gupta) pp. 73-82.
54. Kaur, Amanpreet and Singh, Prati Pal (2003). Biotherapy of rodent malaria by
recombinant mouse granulocyte-macrophage colony-stimulating factor and
methionine-enkephalin co-administration. In Proceedings of the IInd International
Symposium of Molecular Medicine, 2002, Vadaora, pp 205-210.
55. Kaur, Sukhraj and Singh, Prati Pal (2003). Proinflammatory host-defence
activities of mouse serum amyloid P-component against Mycobacterium
tuberculosis H37Rv. In Proceedings of the IInd International Symposium of
Molecular Medicine, 2002,Vadaora, pp 286-290.
56. Singal, Priya; Kinhikar, Arvind G., Singh Savita and Singh, Prati Pal (2003).
Neuroimmunomodulatory effects of morphine in Leishmania donovani-infected
hamsters. Neuroimmunomodulation 10, 261-269. (IF 2002: 1.153)
57. Kaur, A., Kinhikar, A. G. and Singh, Prati Pal (2002). Protection of mice against
Plasmodium yoelii nigeriensis after co-treatment with recombinant mouse
granulocyte-macrophage colony-stimulating factor and synthetic met-enkephalin.
J. Parasit. Dis. 26, 9-21.
Dr. Prati Pal Singh

27
58. Kinhikar, A. G. and Singh, Prati Pal (2002). Production and characterization of
monoclonal antibodies against asexual stages of Plasmodium yoelii nigeriensis.
Hybridoma and Hybridomics 21, 479-485. (IF 2002: 0.574)
59. Kaur, A., Kinhikar, A. G. and Singh, Prati Pal (2002). Malaria vaccine
development: problems and perspectives. Crr. Res. Info. Pharma. Sci. 3, 9-13.
60. Janin, Rahul; Suryanarayana, V., Jain, Meenakshi; Kaur, Navneet; Singh, Savita
and Singh, Prati Pal (2002). Antimalarial activities of ring substituted
bioimidazoles. Bioorganic & Medicinal Chemistry Letters. 12, 1701-1704.
(IF 2002: 2.043)
61. Kinhikar G., Arvind, Singh Savita and Singh, Prati Pal (2001). The co-adjuvant
effect of interleukin-1 fragment peptide 163-171 in a lethal rodent malaria
vaccination model. J. Parasit. Dis. 25, 77-85.
62. Singh, Prati Pal and Singh, Savita (2001). Protection of mice from malaria after
co-administration of recombinant mouse granulocyte-macrophage colony-
stimulating factor and methionine-enkephalin. Eur. Cytokine Netw. 12, 528-536.
(IF 2002: 2.153)
63. Singh S. and Singh P. P. (2001). Serum amyloid P-component-induced colony-

stimulating factors production by macrophages. Scand. J. Immunol. 53, 155-161.
(IF 2003: 1.836)
64. Singh, Savita and Singh, Prati Pal (2000). Morphine-modulation of plasmodial
antigens-induced colony-stimulating factors production by macrophages. Life
Sciences 67, 1035-1045. (IF 2002: 1.824)
65. Singh, Prati Pal (1998). Modern biotechnology in healthcare: the products, the
transition, the business. Pharmag. 10, 26-27.
66. Singh, Rashmi., Gupta, P. P. and Singh, P. P. ( 1998) Cultivation of mouse bone
marrow-derived mast cells using concanavalin-A stimulated splenocyte
supernatant. Ind. J. Pharmacol. 30, 195-198.
67. Hoffman, S.L., Crutcher, J.M., Puri, S.K., Ansari, A.A., Villnger, F., Franke, E.D.,
Singh, P.P., Finkelman, F., Gately, M.K., Dutta, G.P. and Sedegah, M. (1997).
Sterile protection of monkeys against malaria after administration of interleukin-
12. Nature Medicine 3, 80-83. (IF 1998: 28.740)
68. Singh, P. P. and Singh, N.B. (1996). C-reactive protein: Stimulation of monkey
blood monocyte derived macrophages for enhanced phagocytosis of Plasmodium
fragile-infected erythrocytes. Biol. Memoirs 22, 11-19.
69. Singh, P. Pal; Singh, S., Dutta, G.P. and Singh, N.B. (1995). C-reactive protein-
induced colony-stimulating factors production by macrophages. Eur. Cytokine
Netw. 6, 37-43. (IF 1998: 2.122)
Dr. Prati Pal Singh

28
70. Singh, Prati Pal; Singh, Savita and Singh, N. B. (1995). C-reactive protein-
inducedenhanced phagocytosis of Plasmodium fragile-infected erythrocytes by
macrophages. In : Proceedings of the International Symposium on Vectors and
Vector Borne Diseases (Eds. A. P. Dash, K. Satyanarayana), National Academy of
Vector Born Diesases, Bhubaneswar (67-72).
71. Singh, Savita; Singh, Prati Pal; Dhawan, V.C., Haq, W., Mathur, K.B., Dutta,
G.P., Srimal, R.C. and Dhawan, B.N. (1994). Lymphokines production by
concanavalin A-stimulated mouse splenocytes: modulation by met-enkephalin and
a related peptide. Immunopharmacol. 27, 245-251.
72. Singh, Prati Pal; Singh, Savita., Dutta, G.P. and Srimal, R.C. (1994).
Immunomodulation by morphine in Plasmodium berghei-infected mice. Life
Sciences 54, 331-339.
73. Singh, Prati Pal; Singh, Savita; Dhawan, V.C., Haq, W., Mathur, K.B., Dutta G.P.,
Srimal, R.C. and Dhawan, B.N. (1994). Opiate receptors-mediated modulation of
colony-stimulating factors elaboration by macrophages. In : Recent Advances in the
Study of Neurotransmitter Receptors (Eds. B.N. Dhawan, R.C. Srimal, R.
Raghubir, R.S. Rapaka), Central Drug Research Institute, Lucknow (35-47).
74. Singh, Prati Pal; Singh, Savita and Dutta G.P. (1994). Plasmodium berghei
infection in rats: Immune-complexes-induced colony-stimulating factors
elaboration by macrophages. In: Tropical Diseases: Molecular Biology and
Control Strategies (Eds. S. Kumar, A.K. Sen, G.P. Dutta, R.N. Sharma), PID,
CSIR, New Delhi (325-334).
75. Singh, Prati Pal and Dutta, G.P. (1992). Comparative evaluation of the colony-
stimulating factors induction potential of Plasmodium cynomolgi-infected monkey
erythrocytes and soluble antigens. Acta Tropica 51, 247-255.
76. Singh, Prati Pal (1992). Evaluation of immunomodulators at cellular and

molecular levels. UNESCO-CDRI Workshop on the "Use of Pharmacological
Techniques for the Study of Natural Products", Central Drug Research Institute,
Lucknow (49-53).
77. Singh, P.P., Singh, S., Dhawan, V.C., Haq, W., Mathur, K.B., Dutta, G.P., Srimal,
R.C. and Dhawan, B.N. (1991). Enkephalins-modulation of Plasmodium
cynomolgi antigens-induced colony-stimulating factors elaboration by
macrophages. J. Biol. Regul. Homeost. Agents 5, 142-146.
78. Singh, Prati Pal; Dhawan V.C., Haq, W., Mathur, K.B., Dutta, G.P., Srimal, R.C.
and Dhawan, B.N. (1991). Lymphokines elaboration: modulation by enkephalins.
Int. J. Toxicol. Occupat. Environ. Health 1, 199.
79. Singh, P.P. and Dutta G.P. (1991). Induction of colony-stimulating factors by
Plasmodium cynomolgi components. J. Biol. Regul. Homeost. Agents 5, 59-64.
80. Singh, Prati Pal (1991). Interaction of serum amyloid P-component with
macrophages. In: Proceedings of the International Conference on Biomembranes
Dr. Prati Pal Singh
29
in Health and Disease, Vol. 1. (Eds: P.K. Ray, A.M. Kidwai), Today and
Tomorrow's Printers and Publishers, New Delhi (299-303).
81. Singh, Prati Pal and Dutta, G.P.(1991). Lymphokines and macrophage activation
in simian malaria: P. cynomolgi infection in monkeys. In : Proceedings of the
International Conference on Biomembranes in Health and Disease, Vol. 2 (Eds :
P.K. Ray, A.M. Kidwai). Today and Tomorrow's Printers and Publishers, New
Delhi (551-555).
82. Singh, Prati Pal and Dutta, G.P. (1990). Serum colony-stimulating factors
induction in monkeys infected with Plasmodium cynomolgi. In: The Physiological
and Pathological Effects of Cytokines (Eds. C.A. Dinarello, M.J. Kluger, M.C.
Powanda, J.J. Oppenheim). Wiley-Liss, Inc., New York (339-342).
83. Singh, Prati Pal and Dutta, G.P. (1989). Simian malarias-induced lymphokines:
Enhancement of macrophage erythrophagocytosis. Ind. J. Parasit. 13, 281-293.
84. Singh, Prati Pal and Dutta. G.P. (1989). Immune-complexes-mediated evasion of
Plasmodium knowlesi from destruction by macrophages. Acta Tropica 46, 239-247.
85. Singh, Prati Pal and Dutta, G.P. (1988). Plasmodium knowlesi infection in
monkeys: Effects of acute-phase serum on macrophage erythrophagocytosis. Ind.
J. Parasit. 12, 262-274.
86. Singh, Prati Pal; Srivastava, V.B. and Talkwalkar, S. (1987). Natural Entamoeba
muris infection in rats: A new model for screening potential luminal amoebicides.
Ind. J. Parasit. 11, 15-20.
87. Singh, Prati Pal; Gervais, F., Skamene, E. and Mortensen, R.F. (1986). Serum
amyloid P-component induced enhancement of macrophage listericidal activity.
Infect. Immun. 52, 688-694.
88. Singh, Prati Pal and Mortensen, R.F. (1985). Serum amyloid P-component (SAP)
response in inbred mouse strains during Listeria monocytogenes infection. In:
Proceedings of II International Symposium on Genetic Control of Host Resistance
to Infection and Malignancy, Montreal (Ed. E. Skamene), Allan R. Liss, Inc., New
York (339-344).
89. Singh, Prati Pal; Tendulkar, J.S. and Nagarajan, K. (1985). Direct amoebicidal
activity of CG-10213 GO and other nitroimidazoles against axenically grown E.
histolytica. Ind. J. Parasit. 9, 99-100.
90. Dutta, G.P; Singh, Prati Pal: Agarwal, Anju and Agarwal, S.S. (1982). Serological
studies in Plasmodium knowlesi infected convalescent rhesus monkeys. Ind. J.
Med. Res. 75, 212-219.
91. Dutta, G.P., Singh, Prati Pal and Saibaba, P. (1981). Presbytis entellus as a new
host for experimental Plasmodium knowlesi infection. Ind. J. Med. Res. 73, 63-66.
Dr. Prati Pal Singh

30
92. Singh, Prati Pal and Dutta, G.P. (1981). Antimalarial activity of mefloquine and
chloroquine against blood induced Plasmodium knowlesi infection in rhesus
monkeys. Ind. J. Med. Res.73, 23-28.
93. Singh, Prati Pal, Puri, S.K. and Dutta, G.P. (1980). Chemotherapeutic response
of the antigenic variants of Plasmodium knowlesi in Macaca mulatta. Ind. J.
Parasit. 4, 191-193.
94. Singh, Prati Pal (1980). Antibiotic treatment of Assamese monkey Macaca
assamensis infected with Plasmodium knowlesi and their further susceptibility to
reinfection. Ann. Nat. Acad. Med. Sci. (Ind.). 16, 263-270.
95. Dutta, G.P. and Singh, Prati Pal (1980). Immune status of rhesus monkeys
infected with Plasmodium knowlesi after curative and suppressive chloroquine
therapy. Ind. J. Med. Res. 72, 23-32.
96. Singh, Prati Pal (1980). Inhibition of invasion of Plasmodium knowlesi merozoites
by sera from hyperimmunized monkeys and passive transfer of immunity. In:
Proceedings of "International Symposium: Hundred Years of Malaria Research",
Calcutta, (314 -320).
97. Dutta, G.P. and Singh, Prati Pal (1979). Blood schizontocidal activity of some
antibiotics against Plasmodium knowlesi infection in Assamese monkey. Ind. J.
Med. Res. (Suppl.). 70, 91-94.
98. Singh, Prati Pal (1979). Passive transfer of immunity against Plasmodium
knowlesi in rhesus monkeys Macaca mulatta. Ind. J. Parasit. 3, 195-197.
99. Dutta, G.P., Singh, Prati Pal and Banayal, H.S. (1978). Macaca assamensis as a
new host for experimental Plasmodium knowlesi infection. Ind. J. Med. Res. 68,
923-926.
EDITORIALS
1. Singh, Prati Pal (2016). The state of pharmaceutical education and research in
India. J. Pharm. Microbiol. 2, 1-2.
2. Satyanarayana K., Satyanarayana, K., Sharma, Anju; Parikh, Purvish; Vijayan,

V. K., Sahu, D. K., Nayak, Barun K., Gulati, R. K., Parikh, Mahendra N; Singh,
Prati Pal ; Bavdekar, S. B., Sreehari, U., Sahni, Peush (2008). Statement on
publishing clinical trials in Indian biomedical journals. Ind. J. Pediatrics. 75, 755.
3. Singh, Prati Pal (2007). State of the Journal of Parasitic Diseases Address 2007.
J. Parasitic. Dis. 31, 1-2.
4. Satyanarayana K., Satyanarayana, K., Sharma, Anju; Parikh, Purvish; Vijayan,

V. K., Sahu, D. K., Nayak, Barun K., Gulati, R. K., Parikh, Mahendra N; Singh,
Prati Pal ; Bavdekar, S. B., Sreehari, U., Sahni, Peush (2007) Statement on
publishing clinical trials in Indian biomedical journals. J Parasitic Dis. 77-78.
Dr. Prati Pal Singh
31
5. Singh, Prati Pal (2006). A Note from the New Editor-in-Chief. J. Parasitic. Dis.
30, 1-3.
ABSTRACTS/PRESENTATIONS/PARTICIPATIONS (1988 onwards; in reverse

chronological order)
1. Singh, Prati Pal; Sanjeev Sinha, Manish Goyal (2016). Diagnosis of human
tuberculosis: identification of new biomarker(s) and biosignature(s). 17th
International Congress on Infectious Diseases, Hyderabad.
2. Singh, Prati Pal and Amit Goyal (2016). Interleukin-6: a potential biomarker of
the success of tuberculosis treatment. 17th International Congress on Infectious
Diseases, Hyderabad.
3. Singh, Prati Pal (2015) Discovery of antimalarial drugs and apicoplast

biosynthetic pathways. Conference on Drug Discovery & Development: Global
Scenarios-Indian Perspective (Abstr. No. IL-7), Hyderabad.
4. Singh, Prati Pal and Piyush Dave (2015). Effect of vitamin A on the course of
Plasmodium berghei infection mice. 10th Symposium Frontiers in Biomedical
Research. Comprehending genes@ work: From Structural Biology to Drug
Discovery. University of Delhi, Delhi.
5. Singh, Prati Pal (2015). Human malaria vaccine(s) development: the problems and
the silver lining. National Conference on “Emerging Challenges in Biotechnology:
Perspective and Prospective”, Chandigarh Group of Colleges, Landran, S.A.S.
Nagar.
6. Singh, Prati Pal (2015). Malaria: chemotherapy and drug resistance. Chandigarh
Science Congress. Panjab University, Chandigarh.
7. Singh, Prati Pal (2015). Genomics and the discovery of new antimalarial drugs.
National Conference on Infectious Diseases: Challenges and Opportunities in
Research and Practice, Institute of Pharmacy, Nirma University, Ahmedabad.
8. Singh, Prati Pal; Sinha, Sanjeev and Goyal, Manish (2014). Identification of
biomarker(s) for the diagnosis tuberculosis: a study of serum cytokines. National
Conference on Empowering Mankind with Microbial Technologies, Coimbatore.
9. Prakash, Bhanu and Singh, Prati Pal (2014). The blood-schizonticidal activity of
fusidic acid in Plasmodium berghei-infected mice. National Conference on
Empowering Mankind with Microbial Technologies, Coimbatore.
10. Singh, Prati Pal (2014). Bioimmunotherapy of malaria: unknown diamensions and
new frontiers. International Conference on Drugs for the Future: Infectious
Diseases. Antimicrobial Drug Discovery: Challenges and Perspectives (Abstr. No.
IL-7) Hyderabad.
Dr. Prati Pal Singh

32
11. Singh, Prati Pal and Ganesh, Yadaigiri (2014). Curcumin as a possible
immunomodulator for the modulation of plasmodial antigen-induced colony-
stimulating factors elaboration by macrophages. International Conference on Drugs
for the Future: Infectious Diseases. Antimicrobial Drug Discovery: Challenges and
Perspectives (Abstr. No. PP-2) Hyderabad.
12. Amit Goyal and Prati Pal Singh (2012). Is IL-6: a signature molecule for the
diagnosis of Mycobacterium tuberculosis? 15th International congress on Infectious
Diseases, ICID-2012, Bangkok Thailand.
13. Amit Goyal and Prati Pal Singh (2012). Cytokine characterization of clinical
isolates of Mycobacterium tuberculosis collected from northern region of India.
International Science Symposium on HIV and Infectious Diseases, Chennai.
14. Amit Goyal and Prati Pal Singh (2011). Role of M. tuberculosis virulence on
macrophage phagosome maturation: a confocal microscope study. 52nd Annual
Conference of Association of Microbiologists of India, AMI-2011, Chandigarh.
15. Amit Goyal and Prati Pal Singh (2011). Differential elaboration of IL-6 by M.
tuberculosis infected macrophages: implications of virulence and viability. 66th
National Conference on Tuberculosis and Chest Diseases-2011, NATCON-2011,
Dehradun.
16. Amit Goyal and Prati Pal Singh (2011). Diagnosis of M. tuberculosis complex in
clinical sample using polymerase chain reaction. XXXV National Conference of
Indian Association of Medical Microbiologists, MICROCON-2011, Varanasi.
17. Singh, Prati Pal and Goyal, Amit (2011). IL-6: a transcriptional signature of
pathogenic and nonpathogenic mycobacteria. “World Congress on Biotechnology”,
Hyderabad, March 21-23, 2011.
18. Goyal, Amit and Singh, Prati Pal (2011). Macrophage-mycobacterium

interaction: differential induction of macrophage-derived IL-6 cytokine by live and
dead intracellular Mycoacterium. “World Congress on Biotechnology”, Hyderabad,
March 21-23, 2011.
19. Goyal, Amit and Singh, Prati Pal (2011). Secretion of IL-6 by live and dead
pathogenic mycobacteria. “National Conference on Contemporary Trends in
Biological and Pharmaceutical Research”, Pilani, March 12-13, 2011.
20. Patel, K., Jhamb, Sarbjit Singh and Singh, Prati Pal (2010). Metabolic changes in
Mycobacterium tuberculosis during nutrient starvation conditions. 51st Annual
Conference of Association of Microbiologists of India, Ranchi, (Abstr. No. MM-
01, pp 271).
21. Patel, Fenil and Singh, Prati Pal (2010). Blood-schizontocidal activity of a
combination of dapsone and proguanil against rodent malaria: enhancement by
Dr. Prati Pal Singh
33
probenecid. Foundation Day Symposium on Parasitic Infections Then and Now:

with special Reference to India, PGI, Chandigarh, (p. 70).
22. Patel, Kamlesh., Jhamb, Sarbjit Singh and Singh, Prati Pal (2010). Changes in
catalase activity and alpha crystallin expression during nutrient starvation
conditions in Mycobacterium tuberculosis. 3rd National Conference on Infectious
Diseases, New Delhi, (P-224).
23. Jhamb, S. S. and Singh, P. P. (2009). Chemotherapeutic characterization of

Mycobacterium tuberculosis isolates from different parts of India. 50th Annual
Conference of Association of Microbiologists of India, Pune, (MM-017).
24. Singh, Prati Pal and Jhamb, Sarabjit Singh (2009). Morphine,
neuroimmunomodulation and TB: a rodent model. 15th Society on Neuroimmune
Pharmacology Scientific Conference, Wuhan, China.
25. Singh, Prati Pal (2009). Participated in the “14th World Conference on Tobacco or
Health”, Mumbai.
26. Singh, Prati Pal and Goyal, Amit (2009). Tuberculosis: from genetics to molecular
diagnosis and drug resistance. CME-cum-workshop “Molecular techniques in
clinical microbiology”, Lucknow (p. 4).
27. Kharatmal, SB; Jhamb SS and Singh PP (2009). Rapid BACTEC method for in
vitro screening of satranidzole and other drugs against latent Mycobacterium
tuberculosis. 2nd National Conference of AIDS society of India, Jaipur (p. 43).
28. Singh, Prati Pal and Singh, Savita (2008). Hybridomic elucidation and cytokine
characterization of antimalarial imme response: a rodent study. “Keystone
Symposia” Malaria: Immunology, Pathogenesis and Vaccine Perspectives, Austria
(Poster. No. E3-321).
29. Zrinka Rajić, Gabrijela Džimbeg, Branka Zorc1, Ivana Perković, Prati Pal Singh,
Savita Singh (2008). Primaquine conjugates: synthesis and antimalarial evaluation.
XII. Ruzickini dani, Vukovar, Croatia.
30. Singh, Prati Pal and Kaushik Debnath (2008). Antimalarial activity of allicin and
its potential to reduce the curative doses of curcumin and artesunate: a rodent study.
Multi-colloquial Brain Storming Meeting on Vector-borne Diseases. Madurai.
(Oral Presentation No. 7, page 7).
31. Singh, PP and Pratap B. (2008). Possible extension of the working life of
miltefosine by reduction of its curative doses by azithromycin: a rodent visceral
leishmaniasis study. IX International Symposium on Vectors and Vector Borne
Diseases, Puri. (Oral Presentation No. 7, page 13).
32. Singh, PP and Debnath K. (2008). A comparative study of the efficacy of allicin
against different rodent malarias. IX International Symposium on Vectors and
Vector Borne Diseases, Puri. (Abstr. No. P1.84).
Dr. Prati Pal Singh
34
33. Singh, PP and Das NR. (2008). Met-enkephalin suppresses disease progression in
hamster model of visceral leishmaniasis. IX International Symposium on Vectors
and Vector Borne Diseases, Puri. (Abstr. No. P1.85).
34. Singh, Ramanpreet; Jhamb, S. S and Singh, Prati Pal (2008). Immunoenhancing
effects of morphine during murine tuberculosis. International Conference on
Opportunistic Pathogens in AIDS, ICOPA-INDIA2008, New Delhi, (Page. No.
110).
35. Singh, Prati Pal (2007). Genomics and antimalarial drug discovery. National
Symposium on Pharmaceutical Sciences and Pharmacoinformatics, Chandigarh
(Abstr. No. PS-7).
36. Jhamb, Sarbjit Singh; Singh, Raman Preet and Singh, Prati Pal (2006).
Comparative evaluation of BACTEC and plating methods for in vivo screening of
antitubercular drugs. 47th Annual Conference: Association of Microbiologists of
India, Bhopal (Abstr. No. AB-9).
37. Singh, Prati Pal and Singal, Priya (2006). Neuroimmunomodulation in

experimental visceral leishmaniasis: some cellular and molecular mechanisms.18th
National Conference of Parasitology, Kolkata (Invited Talk, Abstr. No. IT-3).
38. Singh, Prati Pal and Singh, Savita (2006). Blood- and tissue-schizontocidal
activities of some substituted 8-aminoquinolines. 8th International Symposium on
Vector & Vector Borne Diseases, Madurai (Plenary Lecture, Abstr. No. 120).
39. Singh, P. P. and Singal, P. (2006). Neuroimmunomodulatory effect of morphine in

murine visceral leishmaniasis. 12th Society on NeuroImmune Pharmacology
Conference, Santa Fe, NM, USA (Abstr. No. TP-39).
40. Kaur, Sukhraj and Singh, Prati Pal (2006). Interaction of Mycobacterium
tuberculosis with macrophages: some in vitro protective effects of serum amyloid
P-component. 10th International Conference of ISCB on Drug Discovery:
perspectives and challenges, Lucknow (Abstr. No. IL-4).
41. Singh, Prati Pal and Kaur, Sukhraj (2005). Innate immune mechanisms in
tuberculosis: the roles of acute-phase reactants. 32nd Annual Conference, Indian
Immunology Society, Chandigarh (Abstr. No. IT-18).
42. Singh, Prati Pal (2005). Silicotuberculosis: some unknown immunological

dimensions. In Silver Jubilee Special Issue of “Toxicology International”,
International Conference on Toxicology, Environment and Occupational Health,
Lucknow (Abstr. No. S7-LP-02).
43. Singh, Prati Pal and Kaur, Amanpreet (2005). Recombinant mouse GM-CSF and
methionine-enkephalin co-treatment-induced protection from Plasmodium
chabaudi chabaudi AS malaria: the role of IFN-γ-dependent synergism.
Dr. Prati Pal Singh

35
International Medicine and Health in the Tropics Congress, Marseille, France

(Abstr. No. P 443, p 230).
44. Kaur, Amanpreet; Gupta, Varsha and Singh, Prati Pal (2005). Recombinant
human GM-CSF and M-ENK co-treatment-induced activation of human blood
monocyte-derived macrophages for the killing of Plasmodium falciparum, in vitro.
International Medicine and Health in the Tropics Congress, Marseille, France
(Abstr. No. P 444, p 230).
45. Kaur, Amanpreet; Gupta, Varsha and Singh, Prati Pal (2005). Recombinant
human GM-CSF and TGG co-treatment-induced activation of human blood
monocyte-derived macrophages for the killing of Plasmodium falciparum, in vitro.
International Training and Research in Emerging Infectious Diseases, Asian
Regional Workshop, New Delhi (P 17).
46. Kaur, Harsimrat and Singh, Prati Pal (2005). Immunomodulation in murine
tuberculosis. International Training and Research in Emerging Infectious Diseases,
Asian Regional Workshop, New Delhi (P 49)
47. Singh, Savita; Vangapandu, Suryanarayana; Jain, Meenakshi; Jain, Rahul and
Singh, Prati Pal (2005). Tissue-schizontocidal activity of a new potent blood-
schizontocide compound NP-96 in P. yoelii nigeriensis-infected mice. 7th
International Symposium on Vectors and Vector Borne Diseases, Punjabi
University, Patiala. (Oral Pres. 14).
48. Singh, Savita; Singh, Prati Pal; Vangapandu, Suryanarayana; Jain, Meenakshi and
Jain, Rahul (2005). Causal prophylactic activity of a new potential antimalarial
compound NP-96 using P. yoelii nigeriensis mice model. 7th International
Symposium on Vectors and Vector Borne Diseases, Punjabi University, Patiala.
(Oral Pres. 15).
49. Kaur, Amanpreet and Singh, Prati Pal (2005). Interleukin-12 and transforming
growth factor-b responses in Plasmodium chabaudi chabaudi AS-infected mice co-
treated with recombinant mouse granulocyte-macrophage colony-stimulating
factor and methionine-enkephalin. 7th International Symposium on Vectors and
Vector Borne Diseases, Punjabi University, Patiala. (P 17).
50. Singh, Prati Pal and Kaur, Amanpreet (2005). Biopharmaceuticals and
infectomics: recombinant mouse granulocyte-macrophage colony-stimulating
factor and met-enkephalin is an effective co-treatment for rodent malaria. Plenary
Lecture. Med Biotech 2005: A National Symposium. Punjabi University, Patiala.
PL 4.
51. Kaur, Amanpreet and Singh, Prati Pal (2005). Recombinant mouse granulocyte-
macrophage colony-stimulating factor and enkephalin fragment peptide Tyr-Gly-
Gly co-treatment induced sterile protection from sporozoite-induced rodent
malaria. XXII Annual Conference of Indian Academy of Neurosciences, Gwalior.
P13.
Dr. Prati Pal Singh

36
52. Singh, Raman Preet, Singh, Jhamb Sarabjit and Singh, Prati Pal (2005).
Neuroimmunomodulatory effect of morphine in murine tuberculosis. XXII Annual
Conference of Indian I Academy of Neurosciences, Gwalior. P32.
53. Jhamb, Sarbjit Singh; Nayyar, Amit; Jain, Rahul and Singh, Prati Pal (2004). In
vitro antituberculosis activity of ring substituted quinolines. 45th Annual
Conference of Association of Microbiologists of India, Karnal. MPM-18.
54. Kaur, Sukhraj and Singh, Prati Pal (2004). Molecular mechanisms of innate
immunity in tuberculosis: Role of serum amyloid P-component-induced
macrophage production of nitric oxide. 45th Annual Conference of Association of
Microbiologists of India, Karnal. MPM-30.
55. Kaur, Amanpreet and Singh, Prati Pal (2004). Recombinant human GM-CSF and
M-ENK co-treatment-induced activation of human blood monocyte-derived
macrophages for the killing of Plasmodium falciparum, in vitro. 45th Annual
Conference of Association of Microbiologists of India, Karnal. MPM-37.
56. Kaur, Sukhraj and Singh, Prati Pal (2004). Serum amyloid P-component inhibits
mycobacterial uptake through macrophage mannose 6-P receptors. 31st Annual
Conference of Indian Immunology Society, Chennai. (Abstr. No. OR-3)
57. Singh, Prati Pal and Singh, Savita (2004). Biopharmaceuticals-induced sterile
protection from sporozoite-induced rodent malaria. 31st Annual Conference of
Indian Immunology Society, Chennai. (Abstr. No. OR-12)
58. Kaur, Amanpreet and Singh, Prati Pal (2004). Interferon- and tumor necrosis
factor-α responses in Plasmodium berghei-infected mice co-treated with
recombinant mouse granulocyte-macrophage colony-stimulating factor and M-
ENK. 31st Annual Conference of Indian Immunology Society, Chennai. (Abstr. No.
PML-2)
59. Singh, Prati Pal and Kaur, Sukhraj (2004). Acute-phase reactants and tuberculosis:
unknown dimensions and new frontiers. International Symposium on Emerging
Trends in Tuberculosis Research. New Delhi.
60. Kaur, Sukhraj and Singh, Prati Pal (2004). High output expression of colony-
stimulating factors by 30 kDa antigen of Mycobacterium tuberculosis. International
Symposium on Emerging Trends in Tuberculosis Research. New Delhi.
61. Kaur, Sukhraj and Singh, Prati Pal (2004). Serum amyloid P-component induction
kinetics in murine tuberculosis. 12th International Conference of Inflammation
Research Association, New York, USA. (Abstr. No. A035)
62. Singh, Prati Pal (2004). Hybridomics and antimalarial immune response. UGC
Sponsored Conference on “Trends in Parasitology”, Chandigarh (p8).
Dr. Prati Pal Singh

37
63. Singh, Savita; Kaur, Amanpreet; Kinhikar, A. G., Gupta, Vrasha and Singh, Prati
Pal (2004). Cultivation of Plasmodium falciparum local isolates and their in vitro
susceptibility to chloroquine and pyrimethamine. UGC Sponsored Conference on
“Trends in Parasitology”, Chandigarh (p17).
64. Singal, Priya and Singh, Prati Pal (2004). Morphine-induced

neuroimmunomodulation in Leishmania donovani-infected hamsters is Th 1
response-dependent. Section: New Biology, 91st Indian Science Congress,
Chandigarh.
65. Kaur, Sukhraj; Kaur , Harsimrat and Singh , Prati Pal (2004) Mycobacterium
tuberculosis H37Rv-induced colony-stimulating factors production by
macrophages and its regulation by cytokines. Section: New Biology, 91st Indian
Science Congress, Chandigarh.
66. Singal, Priya and Singh, Prati Pal (2004). Leishmania donovani amastigotes-
induced colony-stimulating factors production. Section: New Biology, 91st Indian
Science Congress, Chandigarh.
67. Kaur, Aamanpret and Singh, Prati Pal (2004). Plasmodium chabaudi chabaudi AS
infection in mice: erythrophagocytosis and nitric oxide production, ex vivo. Section:
New Biology, 91st Indian Science Congress, Chandigarh.
68. Kaur, Aamanpret and Singh, Prati Pal (2003). Plasmodium chabaudi chabaudi AS
infection in mice: protection by recombinant mouse granulocyte-macrophage
colony-stimulating factor and methionine-enkephalin treatment. 30th Annual
Conference of Indian Immunology Society, Lucknow. (O 17)
69. Kaur, Sukhraj and Singh, Prati Pal (2003). Mycobacterium tuberculosis H37Rv
30 kDa secretory protein-induced colony-stimulating factors production by
macrophages, in vitro. 30th Annual Conference of Indian Immunology Society,
Lucknow. (P 33)
70. Kaur, Sukhraj and Singh, Prati Pal (2003). Combined antimycobacterial activity
of mouse recombinant granulocyte-macrophage colony-stimulating factor and
gatifloxacin against intramacrophage Mycobacterium tuberculosis H37RV, in
vitro. XX VII National Conference of Indian Association of Medical
Microbiologists, Mumbai. (OT-14)
71. Mariappan, T.T., Kaur, Sukhraj; Singh, Prati Pal and Singh, Saranjit. (2003).
Regional gastrointestinal permeability and ant-tubercular activity of isonicotinyl
hydrazone, an interaction product of 3-formylrifamycin and isoniazid. 22nd
IUATLD Eastern Region Conference, Kathmandu, Nepal. (p52)
72. Singal, P., and Singh, P. P. (2003). Immunomodulatory effects of morphine on

Leishmania donovani-infected macrophages: role of nitric oxide. 20th Annual
Session of Indian Academy of Neurosciences, Udaipur (P-14; Annals of
Neurosciences 2003: 10, 29).
Dr. Prati Pal Singh

38
73. Kaur, A. and Singh, P. P. (2003). Enkephalin fragment peptide Tyr-Tyr-Gly and
recombinant granulocyte-macrophage colony-stimulating factor co-treatment of
rodent malaria. 20th Annual Session of Indian Academy of Neurosciences, Udaipur
(P-15; Annals of Neurosciences 2003: 10, 29).
74. Kaur, S. and Singh, P. P. (2003). Opioid receptor-mediated met-enkephalin

augmentation of Mycobacterium tuberculosis H37Rv phagocytosis by
macrophages, in vitro. 20th Annual Session of Indian Academy of Neurosciences,
Udaipur (P-16; Annals of Neurosciences 2003: 10, 30).
75. Knhikar A. G. and Singh, Prati Pal (2003). Development of a new in vitro
erythrocyte-invasion assay using Plasmodium yoelii nigeriensis free-merozoites.
International Symposium and CME on modern trends in malaria, New Delhi (Page
53).
76. Singh, Prati Pal (2003). Production of monoclonal antibodies against blood-stages
of Plasmodium yoelii nigeriensis, and their characterization in terms of merozoite
invasion inhibition and passive transfer of protection. 90th Indian Science Congress,
Bangalore.
77. Kaur, Sukhraj and Singh, Prati Pal (2002). Serum amyloid P-component-mediated
inhibition of the uptake of Mycobacterium tuberculosis by macrophages, in vitro.
43rd Annual Conference of Association of Microbiologists of India, Hissar (Abstr.
No. MVM-21)
78. Singal, Priya and Singh, Prati Pal (2002). C-reactive protein-mediated enhanced
uptake of Leishmania donovani amastigotes by mouse macrophages in vitro.
Sixteenth National Congress of Parasitology, Bareilly (Abstr. No. O.7.1).
79. Kinhikar, Arvind G., and Singh, Prati Pal (2001). Possible in vivo and in vitro
correlates of protection against Plasmodium yoelii nigeriensis: A monoclonal
study. Microbial Biotechnology–Millennium New Vision, Association of
Microbiologists of India, 42nd Annual Conference, Gulbarga (Abstr. No. MVM-
38).
80. Kinhikar A.G., and Singh, P.P. (2001). Cerebral malaria in Plasmodium yoelii
nigeriensis-infected mice: correlation between hypothermia and the production of
pro-inflammatory cytokines. 5th World congress on Inflammation, Edinburgh –
Scotland (Abstract No.W10/04, Inflammation Research, Suppl. 3, Vol. 50, and
Workshop 10: Cytokines, p. s-172).
81. Savita, Singh and Singh, Prati Pal (2001). Drug-susceptibility and antigenic
variation in Plasmodium falciparum, in vitro. International Symposium on Current
Trends in Drug Discovery, Lucknow (Abstr. No.PII-16).
82. Singh, S., and Singh, P. P. (2000). N-linked oligosaccharide glycosylation-

dependent serum amyloid P-component-mediated inhibition of Plasmodium yoelii
Dr. Prati Pal Singh

39
nigeriensis merozoite invasion of mouse erythrocytes. 69th Annual Meeting of the

Society of Biological Chemists (India), Calcutta (Abstr. No.H-2).
83. Kinhikar, Arvind G., and Singh, Prati Pal (2000). Characterization of monoclonal
antibodies from mice refractory to lethal Plasmodium yoelii nigeriensis challenges.
27th Annual Conference of the Indian Immunology Society, Agra (Abstr. No.II (O)
6).
84. Kinhikar, Arvind G., Singh, Savita and Singh, Prati Pal (2000). Interaction of
Plasmodia with macrophages: elucidation of the cellular and molecular basis of
pathogenesis. The Millennium Symposium Malaria 2000. S. A. S. Nagar.
85. Tanu, Bajaj and Singh, Prati Pal (2000). Molecular mechanisms of antigenic
variation in malaria. The Millennium Symposium Malaria 2000. S. A. S. Nagar.
86. Singh, Prati Pal (2000). Experimental non-human primate models in malaria
research. North-West Chapter regional Meeting of Indian Association of Medical
Microbiologist held at ICSSR Complex, Chandigarh (p.7).
87. Kinhikar, Arvind G. and Singh, Prati Pal (2000). Plasmodium yoelii nigeriensis
infection in mice: an experimental cerebral malaria model. North-West Chapter
regional Meeting of Indian Association of Medical Microbiologist held at ICSSR
Complex, Chandigarh (p.6).
88. Singh, Prati Pal (2000). Granulocyte-macrophage colony-stimulating factor and

met-enkephalin-induced protection against murine malaria. XXVI Annual
Conference of the Indian Immunology Society, Mumbai (Abstr. No.I-3.2/5).
89. Singh, Prati Pal and Singh, Savita (2000). Comparative efficacy of azithromycin
and erythromycin against Plasmodium yoelii nigeriensis infection in mice.
Fourteenth National Congress of Parasitology, New Delhi (Abstr. No.O-3.6).
90. Kinhikar A. G. and Singh, Prati Pal (2000). Vaccination of mice against
Plasmodium yoelii nigeriensis : characterization of immune serum using in vitro
merozoite invasion assay. Fourteenth National Congress of Parasitology, New
Delhi (Abstr. No.PS-7.11).
91. Singh, P. P. and Singh, S. (1999). Morphine-inhibition of Leishmania donovani

antigens-induced colony-stimulating factors production by macrophages is pertusis
toxin-sensitive. 4th International Congress of International Society of
Neuroimmunomodulation, Lugano, Switzerland (Abstr. No. P133).
92. Singh, Prati Pal (1999). Development of recombinant protein drugs. Indo-US
Symposium on Recombinant DNA Technology and its Application in Drug
Discovery, S. A. S. Nagar (p. 8-10).
93. Singh, Prati Pal and Singh, Savita (1999). Morphine-modulation of Plasmodial
antigens-induced colony-stimulating factors production by macrophages.13th
National Congress of Parasitology, Bangalore (Abstr. No.143).
Dr. Prati Pal Singh
40
94. Singh, Savita and Singh, Prati Pal (1998). C-reactive protein-induced colony-
stimulating factors by macrophages: inhibition by chloroquine. 9th International
Conference of the Inflammation Research Association, Hereshy, USA (Abstr.
No.6).
95. Singh, Prati Pal and Singh, Shyam ( 1998 ). Phosphorylcholine and Ca2+-induced
conformational changes in C-reactive protein : a fluorescence study. Molecular
Immunology Forum, Sariska (Abstr. No. 8).
96. Singh, Rashmi ; Gupta, P.P. and Singh , P.P. (1997). Cultivation of mouse mast
cells in vitro. Indian Pharmacological Society : Tridecennial Conference, Jammu
(Abstr. No. OR/87).
97. Singh, Prati Pal (1997). Role of cytokines in the development of

immunomodulators and immunoadjuvants. National Seminar on Molecular Basis
of Drug Development, S. A. S. Nagar (Abstr. No.5).
98. Singh, Prati Pal (1994). Induction of colony-stimulating factors by synthetic

glycopeptides. Molecular Immunology Forum. III-Brain storming Sessions on
Molecular Immunology, Bhubaneswar.
99. Singh, Prati Pal; Singh, Savita; Dutta, G.P. and Singh, N.B. (1994). C-reactive
protein-induced enhanced phagocytosis of Plasmodium fragile infected-
erythrocytes by macrophages. IV Symposium on Vector Borne Diseases,
Bhubaneswar ( p.5).
100. Singh, Savita; Naquvi, T., Haq, W., Singh, Prati Pal; Singh, N.B. and
Mathur, K.B. (1994). Effect of dermorphin analogue on the course of P. berghei
infection in mice. IV Symposium on Vector and Vector Borne Diseases,
Bhubaneswar( p.7).
101. Singh, Prati Pal; Singh Savita; Saran, R., Haq, W., Singh, N.B. and
Mathur,K.B. (1994). Induction of colony-stimulating factors by interleukin-1
fragment 163-171 peptide and its analogues. XXI Annual Conference, Indian
Immunology Society, Chandigarh( p.79).
102. Singh Savita; Saran, R., Haq, W., Singh, P.P., Singh, N.B. and Mathur,
K.B. (1994). Modulation of macrophage erythrophagocytosis by human beta-
casein fragment 54-59 peptide and its analogues. XXI Annual Conference, Indian
Immunology Society, Chandigarh, (p.80).
103. Singh, P.P.; Singh, S., Naquvi, T., Dhawan, V.C., Haq, W., Singh, N.B.,
Dutta, G.P., Srimal, R.C., Dhawan, B.N. Mathur, K.B. (1994). Opioid peptides and
immunomodulation. In: Neuropeptides and Immunomodulation: A Satellite
Symposium of XVI International Congress of Biochemistry and Molecular
Biology, Lucknow ( p.5).
104. Srivastava, Ragini; Singh, Prati Pal; Singh, N.B. and Dutta, G.P. (1994).
The effect of splenectomy on the course of Plasmodium yoelii nigeriensis and P.
Dr. Prati Pal Singh
41
berghei infection in rats. XI National Congress of Parasitology, Udaipur (

p.143).
105. Singh, Prati Pal and Srivastava, Ragini (1994). Protocol for indirect
haemagglutination test. In "NAM and Third World Academy Workshop on
Antimalarial Evaluation and Biocide Assay for Control of Malaria", Central Drug
Research Institute, Lucknow (p.72-77).
106. Singh, Prati Pal (1994). Molecular mechanisms of C-reactive protein-

mediated immunoregulation. Second Brainstorming Sessions in Molecular
Immunology, Bombay.
107. Singh, Prati Pal; Singh, Savita; Maheshwari, R.K., Dutta, G.P. and Friedman,
R.M. (1993). Induction of colony-stimulating factors by poly IC:LC. XX Annual
Conference of Indian Immunology Society. Bhopal (p.7).
108. Singh, Savita; Naqvi, T. Haq, W., Singh, Prati Pal; Mathur, K.B., and Dutta, G.P.
(1993). Immunomodulatory activity of dermorpin and a related peptide. XX
Annual Conference of Indian Immunology Society, Bhopal (p.115).
109. Singh, Prati Pal (1993). Colony-stimulating factors in malaria. III Asian Congress
of Parasitology, Lucknow. (Abstract No. MS-1.11).
110. Singh, Savita; Singh, Prati Pal and Dutta, G.P. (1993). Vaccination of mice
against Plasmodium yoelii nigeriensis : Development of a new model for evaluation
of potential adjuvants. III Asian Congress of Parasitology, Lucknow. (Abstract No.
PS-3.28).
111. Singh, Prati Pal and Dutta G.P. (1993). Molecular immunological studies on
macrophages exposed to chloroquine : Inhibition of Plasmodium berghei-antigens-
induced colony-stimulating factors elaboration. III Asian Congress of
Parasitology, Lucknow (Abstract No.OS-3.14).
112. Singh, Prati Pal, Singh Savita and Dutta, G.P.(1993). Interaction of malaria
parasites with macrophages: Elucidation of cellular and molecular events. National
Symposium "Cell Biology of Parasitic Protozoa", Allahabad (Abstract No. A-13).
113. Singh, Prati Pal (1993). Molecular immunomodulation by opioid peptides. Second
Brainstorming Sessions on Molecular Immunology (Sponsored by CSIR- TAB).
New Delhi (p.9).
114. Singh, Prati Pal (1992). Molecular immunoregulation in malaria: Mechanisms of

cytokine induction and their role(s) in host defense. 2nd Immunobiology Meeting
of Young CSIR Scientists (Sponsored by CSIR-TAB) Delhi.
115. Singh, Prati Pal and Dutta, G.P. (1992). C-reactive protein induced colony-
stimulating factors elaboration by macrophages. 2nd International Congress on
Cytokines: Basic Principles and Clinical Applications, Florence, Italy.
Dr. Prati Pal Singh

42
116. Singh, Prati Pal, Dhawan, V.C., Haq, W., Mathur, K.B., Dutta, G.P. Srimal, R.C.
and Dhawan, B.N.(1992). Effect of enkephalins on the colony-stimulating factors
elaboration by malarial antigens stimulated macrophages from monkeys immune
to P. cynomolgi. 2nd International Congress on Cytokines: Basic Principles and
Clinical Applications, Florence, Italy.
117. Singh, Prati Pal and Dutta, G.P. (1992). Immune-complexes induced colony-
stimulating factors elaboration by macrophages. CSIR Golden Jubilee Symposium
on Tropical Diseases: Molecular Biology and Control Strategies, Lucknow, India
(Abstract No.2.5.20).
118. Singh, Prati Pal; Singh Savita and Dutta, G.P. (1990). Immunosuppressive effects
of morphine during murine malaria. XVII Annual Conference of Indian
Immunology Society, Lucknow, India (Abstract No.047).
119. Singh, Prati Pal and Dutta G.P. (1990). Plasmodium cynomolgi soluble antigens-
induced production of colony-stimulating factors. XIV National Congress of
Indian Association of Medical Microbiologists. Vellore. India (Abstract No.MPG-
4).
120. Singh, Prati Pal and Dutta, G.P. (1980). Serum colony-stimulating factors
induction in monkeys infected with Plasmodium cynomolgi. Second International
Workshop on Cytokines, Hilton Head Island, SC, USA (Abstract No.359).
121. Singh, Prati Pal and Dutta, G.P. (1989). Killing of Plasmodium cynomolgi by
secretory products of macrophages activated by lymphokines and recombinant
human interferon-gamma. Second International Workshop on Cytokines. Hilton
Head Island, SC, USA. (Abstract No.272).
122. Singh, P.P. and Dutta, G.P. (1988). Lymphokines and macrophage activation in
simian malaria. International Conference on Biomembrances in Health and
Disease, Lucknow, India.
123. Singh, P.P. (1988) Interaction of serum amyloid P-component with macrophages.
International Conference on Biomembrances in Health and Disease, Lucknow,
India.
124. Singh, Prati Pal and Dutta, G.P. (1988). The role of soluble antigens and immune
complexes in the expression of macrophage-mediated immune responses during P.
knowlesi infection. XXVII Annual Conference of the Association of
Microbiologists of India, Pune, India.
125. Singh, Prati Pal (1987). Serum amyloid P-component (SAP) binding with
macrophages and its effect on their listericidal activity. The Molecular Biology of
Human Diseases: An Asian Perspective, Singapore.
126. Singh, P.P., Srivastava, K.K. and Dutta, G.P. (1987). Macrophage-mediated
mechanisms during acute-phase of P. cynomolgi infection in rhesus monkey. XIV
Annual Conference of the Indian Immunology Society, Srinagar, India.
Dr. Prati Pal Singh
43
127. Singh, Prati Pal and Mortensen, R.F. (1986). Mouse serum amyloid P-component
enhanced macrophage listericidal activity is not influenced by lymphokine or
lipopolysaccharide. FASEB Annual Meeting, St. Louis, MO, USA.
128. Singh, Prati Pal and Mortensen, R.F. (1986). Enhancement of macrophage
listericidal activity by serum amyloid P-component. ASM Annual Meeting,
Washington, D.C., USA.
129. Singh, Prati Pal and Mortensen, R.F. (1985). Serum amyloid P-component (SAP)
response of inbred mouse strains during Listeria monocytogenes infection.
International Symposium on Genetic Control of Host Resistance to Infection and
Malignancy, Montreal, Canada.
Dr. Prati Pal Singh

PP Singh

Uploaded by

Copyright:

Available Formats

PP Singh

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

PP Singh

Uploaded by

Copyright:

Available Formats

CURRICULUM VITAE

PROF. PRATI PAL SINGH Ph. D., F. N. A. Sc., F. I. A. M. Sc.

1975-1976 Proficiency in French; University of Lucknow, Lucknow.

1973-1975 M. Sc.; Zoology (Physiology/Entomology); University of Lucknow. (I

1971-1973 B. Sc.; Chemistry, Botany, Zoology and Gen. English; University of

1988 Indo-US Workshop on Cell Mediated Immunity in Relation to Tropical

Dr. Prati Pal Singh

1989 IUIS -WHO-AIIMS Advanced Immunology Course, New Delhi.

1991 Indo-US Workshop on Current Approaches for Receptor Studies in

1992 Course on Management of Research Programmes, Council of Scientific and

2003 Induction Training Programme for Faculty of NIPER by Education and

PROFESSIONAL POSITIONS (in reverse chronological order)*

2004–present Professor, Pharmacology and Toxicology, and In-charge, Centre for

Dr. Prati Pal Singh

MEMBERSHIPS OF PROFESSIONAL SOCIETIES/ORGANIZATIONS

1. Member, The Neuro Network, USA.

 Member, Senate, National Institute of Pharmaceutical Education and Research, S.

Dr. Prati Pal Singh

 Member, Editorial Board, Toxicology and Forensic Medicine-Open Journal,

Dr. Prati Pal Singh

 Judge, Poster Session, First Annual Research Day Celebrations, Government

 Nominated for Fellow, Indian Science Academy (F. A. Sc.), Bangalore.

Dr. Prati Pal Singh

 Referee, National Academy Science Letters.

Dr. Prati Pal Singh

Issue titled “Human Parasitic Infections of Pharmaceutical and National Health

 June 28, 2013: European Molecular Biology Laboratory, Hamburg, Germany.

Dr. Prati Pal Singh

 Sept. 16, 2005: Departement de Medecine Moleculaire, Institut Pasteur, Paris,

RESEARCH EXPERIENCE (Forty two years)

Broad area of specialization: Life Sciences Education and Research

Brief summary of major scientific contributions

Dr. Prati Pal Singh

Acute-phase reactant biology

Amoebiasis and trichomoniasis

TEACHING EXPERIENCE: (Jan. 1997 onwards)

Special attainments in education

For last nearly 16 years, I am involved in the teaching of biotechnology, microbiology,

Dr. Prati Pal Singh

1. “Vaccination of mice against Plasmodium yoelii nigeriensis and

1. “Molecular mechanisms in pathogenesis in malaria: role of colony-

9. “Experimental studies on the efficacy of nitazoxanide against Trichomonas

Dr. Prati Pal Singh

35. “To determine the blood-schizonticidal activity of fenofibrate against

Dr. Prati Pal Singh

58. “Determination of the effect of L-valine on the phagocytosis of Plasmodium

1. Hybridoma technology: maintenance of myeloma cell line and a hybrid.

(d). Taught the following Courses to M. S. (Pharm.) and Ph. D. students:

Course coordinator: BT-510, BT-511, BT-630, BT-640, BT-650, GE-511, PC-540,

1. “Modulation of Host Cell Interactomics by Intracellular Pathogen Leishmania

Dr. Prati Pal Singh

10. “Selection of antimalarial resistant lines of Plasmodium yoelii and sporogonic

1. “Effect of cigarette smoke inhalation and/or α-tocopherol on pulmonary lipid

Human resource development activities (recognition/honor/award received by P.G./Ph.

Dr. Prati Pal Singh

1. Anti-Plasmodium yoelli nigeriensis monoclonal antibodies. (For details please see

5. Dapsone (DS)-chlorproguanil combination (Lapdap™), though effective against

6. Triclosan, at 50 µg/ml (minimal inhibitory concentration; MIC), was observed to be

1. Bioimmunotherapy of malaria using rmGM CSF and met-enkephalin co-treatment.